US10246509B2 - Restricted immunoglobulin heavy chain mice - Google Patents
Restricted immunoglobulin heavy chain mice Download PDFInfo
- Publication number
- US10246509B2 US10246509B2 US13/653,456 US201213653456A US10246509B2 US 10246509 B2 US10246509 B2 US 10246509B2 US 201213653456 A US201213653456 A US 201213653456A US 10246509 B2 US10246509 B2 US 10246509B2
- Authority
- US
- United States
- Prior art keywords
- human
- gene
- mouse
- heavy chain
- segment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 title claims abstract description 106
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 title claims abstract description 106
- 241000699670 Mus sp. Species 0.000 title abstract description 94
- 241000282414 Homo sapiens Species 0.000 claims abstract description 1158
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 707
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 134
- 210000004027 cell Anatomy 0.000 claims description 96
- 108060003951 Immunoglobulin Proteins 0.000 claims description 94
- 102000018358 immunoglobulin Human genes 0.000 claims description 94
- 150000007523 nucleic acids Chemical group 0.000 claims description 62
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 55
- 108700028369 Alleles Proteins 0.000 claims description 46
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 36
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 36
- 210000000952 spleen Anatomy 0.000 claims description 34
- 210000004602 germ cell Anatomy 0.000 claims description 26
- 230000008707 rearrangement Effects 0.000 claims description 24
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 14
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 14
- 238000012217 deletion Methods 0.000 claims description 12
- 230000037430 deletion Effects 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 10
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 7
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 4
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 226
- 239000000427 antigen Substances 0.000 abstract description 132
- 108091007433 antigens Proteins 0.000 abstract description 132
- 102000036639 antigens Human genes 0.000 abstract description 132
- 238000000034 method Methods 0.000 abstract description 54
- 230000003053 immunization Effects 0.000 abstract description 30
- 230000003612 virological effect Effects 0.000 abstract description 7
- 241000700159 Rattus Species 0.000 description 32
- 101150117115 V gene Proteins 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 27
- 210000001185 bone marrow Anatomy 0.000 description 27
- 239000012634 fragment Substances 0.000 description 24
- 230000028993 immune response Effects 0.000 description 24
- 241000283984 Rodentia Species 0.000 description 22
- 210000004698 lymphocyte Anatomy 0.000 description 22
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 21
- 108700019146 Transgenes Proteins 0.000 description 21
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 230000008685 targeting Effects 0.000 description 18
- 244000052769 pathogen Species 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 101150008942 J gene Proteins 0.000 description 15
- 238000002649 immunization Methods 0.000 description 14
- 241000282412 Homo Species 0.000 description 13
- 230000001717 pathogenic effect Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 230000000392 somatic effect Effects 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 210000005260 human cell Anatomy 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 10
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 10
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 10
- 230000003472 neutralizing effect Effects 0.000 description 10
- 108010001857 Cell Surface Receptors Proteins 0.000 description 9
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 9
- 102000025171 antigen binding proteins Human genes 0.000 description 9
- 108091000831 antigen binding proteins Proteins 0.000 description 9
- 102000006240 membrane receptors Human genes 0.000 description 9
- 230000002093 peripheral effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 8
- 244000052637 human pathogen Species 0.000 description 8
- 230000028996 humoral immune response Effects 0.000 description 8
- 210000003297 immature b lymphocyte Anatomy 0.000 description 8
- 210000003519 mature b lymphocyte Anatomy 0.000 description 8
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 230000003393 splenic effect Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 101150097493 D gene Proteins 0.000 description 7
- 229930193140 Neomycin Natural products 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 229960004927 neomycin Drugs 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 229940124893 Fluvirin Drugs 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 5
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 5
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 5
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 102000054766 genetic haplotypes Human genes 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 5
- 229960000268 spectinomycin Drugs 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 4
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 4
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 description 4
- 102100039564 Leukosialin Human genes 0.000 description 4
- 241000699729 Muridae Species 0.000 description 4
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 3
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 3
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 3
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000010459 TALEN Methods 0.000 description 3
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 102000053391 human F Human genes 0.000 description 3
- 108700031895 human F Proteins 0.000 description 3
- 238000011577 humanized mouse model Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 2
- 208000012657 Atopic disease Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- 241000941423 Grom virus Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241000398750 Muroidea Species 0.000 description 2
- 241000282341 Mustela putorius furo Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 241000121210 Sigmodontinae Species 0.000 description 2
- 101150067314 aadA gene Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940124691 antibody therapeutics Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000010228 ex vivo assay Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229960001226 live attenuated influenza Drugs 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 241001515942 marmosets Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000011714 129 mouse Methods 0.000 description 1
- 101150082072 14 gene Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000043853 ADAMTS13 Human genes 0.000 description 1
- 108091005670 ADAMTS13 Proteins 0.000 description 1
- 241000699725 Acomys Species 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- 241000398949 Calomyscidae Species 0.000 description 1
- 241000700193 Calomyscus Species 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000398985 Cricetidae Species 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 241001095404 Dipodoidea Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241001416537 Gliridae Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000746783 Homo sapiens Cytochrome b-c1 complex subunit 6, mitochondrial Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 208000035888 Immune-mediated thrombotic thrombocytopenic purpura Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100029572 Immunoglobulin kappa constant Human genes 0.000 description 1
- 101710139965 Immunoglobulin kappa constant Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241001046461 Lophiomys imhausi Species 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699669 Mus saxicola Species 0.000 description 1
- 241000398990 Nesomyidae Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241001338313 Platacanthomyidae Species 0.000 description 1
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000024530 Primary cutaneous B-cell lymphoma Diseases 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 108010052160 Site-specific recombinase Proteins 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 241000398956 Spalacidae Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000004886 acquired thrombotic thrombocytopenic purpura Diseases 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 101150062912 cct3 gene Proteins 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 102000048638 human UQCRH Human genes 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 108700039855 mouse a Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003608 titanium Chemical class 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Definitions
- Non-human animals that are genetically engineered at an immunoglobulin heavy chain variable (V) region locus (or in a transgene) to make antibodies from a restricted number of immunoglobulin heavy chain variable (V H ) segments (or a single V H segment) and/or variants thereof.
- Non-human animals that have a human heavy chain variable domain derived from a single immunoglobulin heavy chain variable gene segment, e.g., human immunoglobulin V H 1-69 gene segment or human V H 1-2 gene segment.
- Non-human animals e.g., mice
- Mice with humanized variable region loci e.g., V H , D H , and J H genes, and V L and J L genes
- V H , D H , and J H genes, and V L and J L genes are used to generate cognate heavy and light chain variable domains for use in antibody therapeutics.
- Other mice are available that generate fully human antibodies with cognate heavy and light chains.
- Human antibody therapeutics are engineered based on desired characteristics with respect to certain pre-selected antigens.
- Humanized mice are immunized with the pre-selected antigens, and the immunized mice are used to generate antibody populations from which to identify high-affinity cognate heavy and light variable domains with desired binding characteristics.
- Some humanized mice such as those having a humanization of just variable regions at endogenous mouse loci, generate populations of B cells that are similar in character and number to wild-type mouse B cell populations. As a result, an extremely large and diverse population of B cells is available in these mice from which to screen antibodies, reflecting a large number of different immunoglobulin rearrangements, to identify heavy and light variable domains with the most desirable characteristics.
- V variable
- B cells that express only certain V segments that bind that particular antigen with sufficiently high affinity and specificity.
- Some such antigens are clinically significant, i.e., a number are well-known human pathogens.
- V segment expressed in the human immune response is a V segment that, in combination with a human D and a human J segment, is more likely to generate a useful high affinity antibody than a randomly selected V segment that has not been observed in a human antibody response to that antigen.
- non-human animals such as, e.g., mice, rats, rabbits, etc.
- biological systems engineered to have a committed humoral immune system for clonally selecting antibody variable sequences derived from restricted, pre-selected V segments, including but not limited to cognate human heavy and light chain variable domains, useful in the manufacture of human antibody-based therapeutics against selected antigens, including certain human pathogens.
- therapeutic antibodies that are capable of neutralizing viral antigens, e.g., HIV and HCV, including antigen-specific antibodies containing heavy chains derived from a single human variable segment, and for a system that produces a diverse source of antibodies from which to select therapeutic antibody sequences.
- viral antigens e.g., HIV and HCV
- antigen-specific antibodies containing heavy chains derived from a single human variable segment e.g., HIV and HCV
- system that produces a diverse source of antibodies from which to select therapeutic antibody sequences.
- further methods and non-human animals for making useful antibodies including antibodies that comprise a repertoire of heavy chains derived from a single human V H segment and having a diverse set of CDR sequences, and including such heavy chains that express with cognate human light chain variable domains.
- Methods are needed for selecting CDRs for immunoglobulin-based binding proteins that provide an enhanced diversity of binding proteins from which to choose, and enhanced diversity of immunoglobulin variable domains, including compositions and methods for generating somatically mutated and clonally selected immunoglobulin variable domains for use, e.g., in making human therapeutics.
- V genes, V H genes, V H gene segments, or V gene segments comprise a restricted number of different heavy chain variable region gene segments (i.e., V genes, V H genes, V H gene segments, or V gene segments), e.g., no more than one, two, or three different V genes; or no more than one V gene segment family member present, e.g., in a single copy or in multiple copies and/or comprising one or more polymorphisms.
- Loci are provided that are capable of rearranging and forming a gene encoding a heavy chain variable domain that is derived from a V H gene repertoire that is restricted, e.g., that is a single V H gene segment or selected from a plurality of polymorphic variants of the single V H gene segment.
- Modified immunoglobulin loci include loci that comprise human immunoglobulin sequences are provided, e.g., a human V segment operably linked to a human or (or human/non-human chimeric) non-human immunoglobulin constant sequence (and in operable linkage with, e.g., a D and/or a J segment).
- Modified loci that comprise multiple copies of a single V H gene segment, including wherein one or more of the copies comprises a polymorphic variant, are provided.
- Non-human animals comprising such humanized loci are also provided.
- Non-human animals have a reduced immunoglobulin heavy chain variable gene segment complexity (i.e., a limited number of heavy chain variable gene segments, or a limited heavy chain variable gene repertoire), wherein the reduced immunoglobulin heavy chain variable gene segment complexity is characterized by the presence of no more than one or no more than two heavy chain variable gene segments, and wherein the heavy chain variable genes present are operably linked to a human or non-human constant region sequence.
- a reduced immunoglobulin heavy chain variable gene segment complexity i.e., a limited number of heavy chain variable gene segments, or a limited heavy chain variable gene repertoire
- the reduced immunoglobulin heavy chain variable gene segment complexity is characterized by the presence of no more than one or no more than two heavy chain variable gene segments, and wherein the heavy chain variable genes present are operably linked to a human or non-human constant region sequence.
- Non-human animals have a reduced immunoglobulin heavy chain variable gene segment complexity (e.g., a single V H gene segment, or a limited number of V H gene segments that are polymorphic variants of a single V H gene segment), wherein the reduced immunoglobulin heavy chain variable gene segment complexity is characterized by the presence of a single V H gene segment or a plurality of V H gene segments that are polymorphic forms of a single V H gene segment (e.g., V H gene segments associated with high copy number and/or polymorphism in humans), and wherein the heavy chain variable genes present are operably linked to a human or non-human constant region sequence.
- the heavy chain variable genes present are operably linked to one or more D and/or one or more J gene segments in the germline of the non-human animal.
- Non-human animals comprise an immunoglobulin heavy chain variable locus (e.g., on a transgene or as an insertion or replacement at an endogenous non-human animal heavy chain variable locus) that comprises a single V H segment operably linked to a D and/or J gene segment.
- the single V H gene segment is operably linked to one or more D and/or one or more J gene segments at the endogenous immunoglobulin heavy chain variable gene locus of the non-human animal.
- Non-human animals are provided that are modified at their immunoglobulin heavy chain variable region loci to delete all or substantially all (e.g., all functional segments, or nearly all functional segments) endogenous immunoglobulin V H segments and that comprise a human V H 1-69 segment (or a human V H 1-2 segment) operably linked to a D and J segment or a J segment at the endogenous immunoglobulin heavy chain variable region locus of the non-human animal.
- Non-human animals are also provided that are modified at their immunoglobulin heavy chain variable region loci to render the endogenous variable region loci incapable of rearranging to form a functional heavy chain comprising endogenous variable region gene segments; wherein the non-human animals comprise a single human variable gene segment (a human V H 1-2 or a human V H 1-69 gene segment) operably linked to a D and a J segment or a J segment at the endogenous immunoglobulin heavy chain variable region locus of the non-human animal.
- a single human variable gene segment a human V H 1-2 or a human V H 1-69 gene segment
- Non-human animals comprise a restricted number (e.g., no more than one, or no more than two) of heavy chain gene segments operably linked to a human or non-human constant region sequence.
- the no more than one or no more than two heavy chain gene segments linked to the constant region sequence are on a transgene, e.g., are at a position other than an endogenous heavy chain locus.
- the human immunoglobulin sequences are derived from a repertoire of immunoglobulin V sequences that consist essentially of a single human V segment, e.g., V H 1-69 or V H 1-2, and one or more D and J segments or one or more J segments. Methods for making human immunoglobulin sequences in non-human animals, tissues, and cells are provided, wherein the human immunoglobulin sequences bind a pathogen.
- mice characterized by a restricted immunoglobulin heavy chain locus wherein the restriction is with respect to the number of immunoglobulin V H gene segments.
- the restriction is to one or no more than two, or a single V H gene family member (e.g., one or more V H alleles, variants, or polymorphic variants thereof).
- the heavy chain locus further comprises one or more D H gene segments and one or more J H gene segments.
- the V H , D H and J H gene segments are human.
- the V H , D H and J H gene segments are operably linked to a non-human constant region (e.g., an IgM and/or an IgG).
- the constant region is a mouse or rat constant region.
- a method for making a mouse having a restricted immunoglobulin heavy chain locus comprising introducing a nucleic acid construct as described herein into a mouse embryonic stem (ES) cell, and isolating or identifying a mouse ES cell that comprises the nucleic acid construct.
- ES mouse embryonic stem
- the nucleic acid construct comprises a single human V H gene segment, one or more human D H gene segments, and one or more human J H gene segments. In one embodiment, the nucleic acid construct comprises one or more site-specific recombination sites (e.g., a loxP or a Frt site).
- site-specific recombination sites e.g., a loxP or a Frt site.
- a mouse made using a targeting vector, nucleic acid sequence, or cell as described herein comprises a DNA sequence that contains a single human V H gene segment (or polymorphic variants thereof), one or more human D H gene segments, and one or more human J H gene segments operably linked to a non-human constant gene.
- a method for making a mouse comprising a restricted immunoglobulin heavy chain locus comprising replacing a mouse immunoglobulin heavy chain locus with a human genomic sequence comprising a single human V H gene segment (or polymorphic variants thereof), one or more human D H gene segments, and one or more human JH gene segments, wherein the human V H , D H and J H gene segments are capable of rearranging to form a chimeric heavy chain that contains a human variable domain operably linked to a non-human constant region.
- the non-human constant region is a mouse or rat constant region.
- the non-human animals are rodents.
- the rodents are mice and/or rats.
- a modified immunoglobulin heavy chain locus that comprises a heavy chain V segment repertoire that is restricted with respect to the identity of the V segment, and that comprises one or more D segments and one or more J segments, or one or more J segments.
- the heavy chain V segment is a human segment.
- the one or more D segments are human D segments.
- the one or more J segments are human J segments.
- the one or more D segments and one or more J segments are human D and human J segments.
- the modified locus is a non-human locus. In one embodiment, the non-human locus is modified with at least one human immunoglobulin sequence.
- the restriction is to one V segment family member. In one embodiment, the one V segment family member is present in two or more copies. In one embodiment, the one V segment family member is present as two or more variants (e.g., two or more polymorphic forms of the V segment family member). In one embodiment, the one V segment is a human V segment family member. In one embodiment, the one V segment family member is present in a number of variants as is observed in the human population with respect to that variant. In one embodiment, the V segment family member is selected from Table 1. In one embodiment, the V segment family member is present in a number of variants as shown, for each V segment, in a number of alleles from 1 allele to the number of alleles shown in the right column of Table 1.
- the restriction is to a human V H 1-69 gene segment.
- the human V H 1-69 gene segment is present in two or more copies.
- the human V H 1-69 gene segment is present as two or more variants (e.g., two or more polymorphic forms the human V H 1-69 gene).
- the human V H 1-69 gene segment is present in a number of variants as is observed in the human population with respect to the human V H 1-69 gene segment.
- the human V H 1-69 gene segment is selected from Table 2.
- the human V H 1-69 gene segment is present in a number of variants as shown, for each V H 1-69 gene segment, in a number of alleles from one allele to the number of alleles shown in Table 2.
- the restriction is to a human V H 1-2 gene segment.
- the human V H 1-2 gene segment is present in two or more copies.
- the human V H 1-2 gene segment is present as two or more variants (e.g., two or more polymorphic forms the human V H 1-2 gene).
- the human V H 1-2 gene segment is present in a number of variants as is observed in the human population with respect to the human V H 1-2 gene segment.
- the human V H 1-2 gene segment is selected from Table 3.
- the human V H 1-2 gene segment is present in a number of variants as shown, for each V H 1-2 gene segment, in a number of alleles from one allele to the number of alleles shown in Table 3.
- a heavy chain immunoglobulin locus comprises a single functional human V segment.
- the single functional human V segment is selected from a V H 1-2, V H 1-3, V H 1-8, V H 1-18, V H 1-24, V H 1-45, V H 1-46, V H 1-58, V H 1-69, V H 2-5, V H 2-26, V H 2-70, V H 3-7, V H 3-9, V H 3-11, V H 3-13, V H 3-15, V H 3-16, V H 3-20, V H 3-21, V H 3-23, V H 3-30, V H 3-30-3, V H 3-30-5, V H 3-33, V H 3-35, V H 3-38, V H 3-43, V H 3- 48, V H 3-49, V H 3-53, V H 3-64, V H 3-66, V H 3-72, V H 3-73, V H 3-74, V H 4-4, V H 4-28, V H 4-30-1, V H 4-30-2, V H 4-30-4, V H 4-31
- the single functional human V segment is a V H 1-69 segment; in a specific embodiment, the single functional human V segment is present in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 polymorphic forms found in the human population. In one embodiment, the single functional human V segment is a V H 1-2 segment; in a specific embodiment, the single functional human V segment is present in 1, 2, 3, 4, or 5 polymorphic forms found in the human population.
- the heavy chain immunoglobulin locus is a modified locus of a non-human animal.
- the modified non-human immunoglobulin heavy chain locus is present in the non-human animal at a position in the genome in which the corresponding unmodified non-human locus is found in the wild-type non-human animal.
- the modified non-human immunoglobulin heavy chain locus is present on a transgene in a non-human animal.
- the single functional human V gene segment is a V H 1-69 gene segment.
- the V H 1-69 gene segment comprises SEQ ID NO: 34.
- the V H 1-69 gene segment is derived from SEQ ID NO: 34.
- the V H 1-69 gene segment is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to SEQ ID NO: 34.
- the single functional human V gene segment is encoded by the nucleotide sequence of SEQ ID NO: 34.
- the single functional human V gene segment is a V H 1-2 gene segment.
- the V H 1-2 gene segment comprises SEQ ID NO: 60.
- the V H 1-2 gene segment is derived from SEQ ID NO: 60.
- the V H 1-2 gene segment is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to SEQ ID NO: 60.
- the single functional human V gene segment is encoded by the nucleotide sequence of SEQ ID NO: 60.
- the single functional human V segment is operably linked to one or more D segments and one or more J segments, or one or more J segments.
- the V segment and one or more D and/or J segments are operably linked to an immunoglobulin heavy chain constant region sequence.
- the immunoglobulin heavy chain constant region sequence is selected from a C H 1, a hinge, a C H 2, a C H 3 sequence, and a combination thereof.
- the C H 1, hinge, C H 2, C H 3, or combination thereof are each non-human endogenous constant sequences.
- at least one of the C H 1, hinge, C H 2, C H 3, or combination thereof is a human sequence.
- the C H 1 and/or hinge are human sequences.
- a modified endogenous non-human immunoglobulin heavy chain locus comprising a replacement of all functional V gene segments with a single human V gene segment (or a single human V gene segment present in multiple polymorphic forms or copy number), wherein the non-human immunoglobulin heavy chain locus is incapable of rearrangement to form a heavy chain variable gene that is derived from a V gene segment other than the single human V gene segment (or one of the polymorphic forms or copies).
- the single human V gene segment is V H 1-69. In one embodiment, the single human V gene segment is V H 1-2.
- the locus comprises at least one human or non-human D H gene segment, and one human or non-human J H gene segment.
- the locus comprises a human D H gene segment and a human J H gene segment.
- the locus comprises a human J H gene segment.
- the locus comprises a human V H 1-69 gene segment (present as a single copy or multiple copies of different polymorphic variants), all functional human D H gene segments, and all functional human J H gene segments.
- the locus comprises a human V H 1-2 gene segment (present as a single copy or multiple copies of different polymorphic forms), all functional human D H gene segments, and all functional human J H gene segments.
- the human V, D, and J gene segments are operably linked to a mouse constant region gene at an endogenous mouse heavy chain locus.
- the mouse heavy chain locus comprises a wild-type repertoire of mouse immunoglobulin constant region sequences.
- a genetically modified non-human animal wherein the only functional immunoglobulin heavy chain V gene segment of the non-human animal is selected from a human V H 1-2, V H 1-3, V H 1-8, V H 1-18, V H 1-24, V H 1-45, V H 1-46, V H 1-58, V H 1-69, V H 2-5, V H 2-26, V H 2-70, V H 3-7, V H 3-9, V H 3-11, V H 3-13, V H 3-15, V H 3-16, V H 3-20, V H 3-21, V H 3-23, V H 3-30, V H 3-30-3, V H 3-30-5, V H 3-33, V H 3-35, V H 3-38, V H 3-43, V H 3-48, V H 3- 49, V H 3-53, V H 3-64, V H 3-66, V H 3-72, V H 3-73, V H 3-74, V H 4-4, V H 4-28, V H 4-30-1, V H 4-30-2, V H 4-30-4, V H 4-
- a genetically modified non-human animal comprising a single functional human V H gene segment (present as a single copy or multiple copies of different polymorphic forms), and wherein the non-human animal is substantially incapable of forming a rearranged immunoglobulin heavy chain variable domain gene that lacks the single functional human V H gene segment (or one of the polymorphic forms or copies).
- a genetically modified non-human animal wherein the only immunoglobulin heavy chain variable region expressed in the non-human animal is derived from one of a human segment selected from a human V H 1-2, V H 1-3, V H 1-8, V H 1-18, V H 1-24, V H 1-45, V H 1-46, V H 1-58, V H 1-69, V H 2-5, V H 2-26, V H 2-70, V H 3-7, V H 3- 9, V H 3-11, V H 3-13, V H 3-15, V H 3-16, V H 3-20, V H 3-21, V H 3-23, V H 3-30, V H 3-30-3, V H 3-30-5, V H 3- 33, V H 3-35, V H 3-38, V H 3-43, V H 3-48, V H 3-49, V H 3-53, V H 3-64, V H 3-66, V H 3-72, V H 3-73, V H 3-74, V H 4-4, V H 4-28, V H 4-30-1, V H 4-30-2, V H
- the human segment is a V H 1-69 segment. In one embodiment, the human segment is a V H 1-2 segment. In one embodiment, the only immunoglobulin heavy chain variable region expressed by the mouse is derived from a single V segment family member, and in one embodiment the only immunoglobulin heavy chain variable region is derived from a polymorphic variant of the single V segment family member.
- a non-human animal comprising a restricted immunoglobulin heavy chain V gene segment repertoire
- the non-human animal further comprises one or more human immunoglobulin ⁇ light chain variable segments (V ⁇ ).
- V ⁇ human immunoglobulin ⁇ light chain variable segments
- the one or more V ⁇ segments are operably linked to one or more human J segments.
- the J segments are human J ⁇ segments.
- the non-human animal does not express an immunoglobulin ⁇ light chain.
- the non-human animal does not comprise a functional human or functional endogenous immunoglobulin ⁇ light chain variable locus.
- the non-human animal is a rodent.
- the rodent is a mouse.
- the non-human animal comprises a replacement at the endogenous non-human immunoglobulin V ⁇ locus of all or substantially all functional endogenous V ⁇ segments with one or more functional human V ⁇ segments.
- the replacement is with all or substantially all functional human immunoglobulin V ⁇ segments.
- the non-human animal comprises a replacement at the endogenous non-human immunoglobulin V ⁇ locus of all or substantially all functional endogenous V ⁇ gene segments with human V ⁇ gene segments selected from V ⁇ 4-1, V ⁇ 5-2, V ⁇ 7-3, V ⁇ 2-4, V ⁇ 1-5, V ⁇ 1-6, V ⁇ 3-7, V ⁇ 1-8, V ⁇ 1-9, V ⁇ 2-10, V ⁇ 3-11, V ⁇ 1-12, V ⁇ 1-13, V ⁇ 2-14, V ⁇ 3-15, V ⁇ 1-16, V ⁇ 1-17, V ⁇ 2-18, V ⁇ 2-19, V ⁇ 3-20, V ⁇ 6-21, V ⁇ 1-22, V ⁇ 1-23, V ⁇ 2-24, V ⁇ 3-25, V ⁇ 2-26, V ⁇ 1-27, V ⁇ 2-28, V ⁇ 2-29, V ⁇ 2-30, V ⁇ 3-31, V ⁇ 1-32, V ⁇ 1-33, V ⁇ 3-34, V ⁇ 1-35, V ⁇ 2-36, V ⁇ 1-37, V ⁇ 2-38, V ⁇ 1-39, V ⁇ 2-40, and a combination thereof.
- the non-human animal comprises a replacement at the endogenous non-human immunoglobulin J ⁇ locus of all or substantially all functional endogenous non-human immunoglobulin J ⁇ segments with one or more functional human immunoglobulin J ⁇ segments.
- the replacement is with all or substantially all functional human immunoglobulin J ⁇ segments.
- the non-human animal comprises a replacement at the endogenous non-human immunoglobulin J ⁇ locus of all or substantially all functional endogenous non-human immunoglobulin J ⁇ gene segments with human J ⁇ gene segments selected from J ⁇ 1, J ⁇ 2, J ⁇ 3, J ⁇ 4, J ⁇ 5, and a combination thereof.
- the non-human animal comprises an immunoglobulin heavy chain variable region locus that comprises a repertoire of V segments consisting essentially of a single V segment and/or polymorphic variants thereof.
- the single immunoglobulin heavy chain V segment is a human V H 1-69 segment
- the non-human animal further comprises a replacement of all functional non-human D H segments with all functional human D H segments, and further comprises a replacement of all functional non-human J H segments with all functional human J H segments
- the immunoglobulin heavy chain variable region locus is operably linked to a human or non-human constant region gene sequence.
- the constant region gene sequence is an endogenous non-human constant region gene sequence.
- the non-human animal rearranges segments at the non-human immunoglobulin heavy chain locus to form a gene encoding heavy chain variable region comprising a human V H 1-69 sequence, a human D H sequence, a human J H sequence, and a mouse constant region sequence.
- the non-human animal comprises an immunoglobulin heavy chain variable region locus that comprises a repertoire of V segments consisting essentially of a single V segment and/or polymorphic variants thereof.
- the single immunoglobulin heavy chain V segment is a human V H 1-2 segment
- the non-human animal further comprises a replacement of all functional non-human D H segments with all functional human D H segments, and further comprises a replacement of all functional non-human J H segments with all functional human J H segments, and wherein the immunoglobulin heavy chain variable region locus is operably linked to a human or non-human constant region gene sequence.
- the constant region gene sequence is an endogenous non-human constant region gene sequence.
- the non-human animal rearranges segments at the non-human immunoglobulin heavy chain locus to form a gene encoding heavy chain variable region comprising a human V H 1-2 sequence, a human D H sequence, a human J H sequence, and a mouse constant region sequence.
- a B cell that comprises the rearranged gene.
- the B cell is from a mouse as described that has been immunized with an antigen of interest, and the B cell encodes an antibody that specifically binds the antigen of interest.
- the antigen of interest is a pathogen.
- the pathogen is selected from an influenza virus, a hepatitis virus (e.g., hepatitis B or hepatitis C virus), and a human immunodeficiency virus.
- the B cell encodes a somatically mutated, high affinity (e.g., about 10 ⁇ 9 K D or lower) antibody comprising a human light chain variable region (e.g., a human ⁇ light chain variable region) that specifically binds the antigen of interest.
- a somatically mutated, high affinity e.g., about 10 ⁇ 9 K D or lower
- a human light chain variable region e.g., a human ⁇ light chain variable region
- a non-human animal comprising a restricted immunoglobulin heavy chain V segment repertoire
- the non-human animal comprises one or more human ⁇ light chain variable (V ⁇ ) segments.
- the one or more human V ⁇ segments are operably linked to one or more human J segments.
- the J segments are human J ⁇ segments.
- the non-human animal does not express a ⁇ light chain.
- the non-human animal does not comprise a functional human or non-human ⁇ light chain variable locus.
- the non-human animal comprises a replacement of all or substantially all functional non-human immunoglobulin V ⁇ segments with one or more functional human immunoglobulin V ⁇ segments.
- the replacement is with all or substantially all functional human immunoglobulin V ⁇ segments.
- the non-human animal comprises a replacement of all or substantially all functional non-human V ⁇ segments with a fragment of cluster A of the human ⁇ light chain locus.
- the fragment of cluster A of the human ⁇ light chain locus comprises human V ⁇ gene segments V ⁇ 3-27 through V ⁇ 3-1.
- the non-human animal comprises a replacement of all or substantially all functional non-human V ⁇ segments with a fragment of cluster B of the human ⁇ light chain locus.
- the fragment of cluster B of the human ⁇ light chain locus comprises human V ⁇ gene segments V ⁇ 5-52 through V ⁇ 1-40.
- the non-human animal comprises a replacement of all or substantially all functional non-human V ⁇ segments with a fragment of cluster A and a fragment of cluster B of the human ⁇ light chain locus, wherein as a result of the replacement comprise human V ⁇ gene segments V ⁇ 5-52 through V ⁇ 3-1.
- the non-human animal comprises a replacement of all or substantially all functional non-human V ⁇ segments with at least 12 human V ⁇ gene segments, at least 28 human V ⁇ , gene segments, or at least 40 human V ⁇ gene segments.
- the non-human animal comprises a replacement of all or substantially all functional non-human immunoglobulin J ⁇ gene segments with one or more functional human immunoglobulin J ⁇ gene segments.
- the replacement is with all or substantially all functional human immunoglobulin J ⁇ gene segments.
- the functional human J ⁇ gene segments include J ⁇ 1, J ⁇ 2, J ⁇ 0.3 and J ⁇ 7.
- the non-human animal comprises an immunoglobulin heavy chain variable (V H ) region locus that comprises only a single V H segment, wherein the single V H segment is a human V H 1-69 segment or a human V H 1-2 segment, and further comprises a replacement of all functional non-human D H segments with all functional human D H segments, and further comprises a replacement of all functional non-human J H segments with all functional human J H segments, and wherein the V H region locus is operably linked to a human or non-human constant region gene sequence.
- the constant region gene sequence is a non-human constant region gene sequence, e.g., an endogenous non-human constant gene sequence.
- the non-human animal rearranges segments at the non-human immunoglobulin heavy chain locus to form a gene encoding an immunoglobulin heavy chain variable region comprising a human V H 1-69 sequence (or a human V H 1-2 sequence), a human D H sequence, a human J H sequence, and an endogenous non-human constant region sequence.
- a B cell that comprises the rearranged gene.
- the B cell is from a non-human animal as described that has been immunized with an antigen of interest, and the B cell encodes an antibody that specifically binds the antigen of interest.
- the antigen is a human protein selected from a ligand, a cell surface receptor and an intracellular protein.
- the antigen of interest is a pathogen.
- the pathogen is selected from an influenza virus, a hepatitis virus (e.g., hepatitis B or hepatitis C virus), and a human immunodeficiency virus.
- the B cell encodes a somatically mutated, high affinity (e.g., about 10 ⁇ 9 K D or lower) antibody comprising a human light chain variable region (e.g., a human ⁇ light chain variable region) that specifically binds the antigen of interest.
- a somatically mutated, high affinity e.g., about 10 ⁇ 9 K D or lower
- a human light chain variable region e.g., a human ⁇ light chain variable region
- a non-human animal comprising a restricted immunoglobulin V H segment repertoire
- the non-human animal comprises a human V H 1-69 segment (or a human V H 1-2 segment) on a transgene
- the human V H 1-69 segment is operably linked on the transgene to a human or non-human D H segment, and/or a human or non-human J segment
- the transgene further comprises a human or non-human constant region gene, or a chimeric human/non-human constant region (e.g., a C H 1, hinge, C H 2, C H 3 or combination thereof wherein at least one sequence is non-human, e.g., selected from hinge, C H 2, and C H 3 and/or hinge).
- the non-human animal is a mouse or rat and the non-human D, J, and/or constant region gene is a mouse or rat gene or chimeric human/mouse or rat.
- the non-human animal comprises a transgene that comprises an immunoglobulin light chain variable region locus that comprises one or more human immunoglobulin V ⁇ gene segments and J ⁇ gene segments, or one or more human immunoglobulin V ⁇ gene segments and J ⁇ gene segments, and a human immunoglobulin ⁇ or ⁇ light chain constant region gene, such that the transgene rearranges in the non-human animal to form a rearranged immunoglobulin ⁇ or ⁇ light chain gene.
- the human V ⁇ and J ⁇ gene segments are those described herein.
- the human V ⁇ and J ⁇ gene segments are those described herein.
- the non-human animal comprises a transgene having an immunoglobulin heavy chain variable locus that comprises a single V segment that is a human V H 1-69 segment (or a human V H 1-2 segment), one or more human D segments, one or more human J segments, and a human constant gene operably linked to the heavy chain variable locus, such that the mouse expresses from the transgene a fully human antibody derived from the V H 1-69 segment (or the V H 1-2 segment).
- the non-human animal does not comprise a functional endogenous immunoglobulin heavy chain variable region locus.
- the non-human animal comprises a nonfunctional endogenous immunoglobulin heavy chain variable region locus that comprises a deletion of an endogenous non-human D H and/or endogenous non-human J H segment, such that the non-human animal is incapable of rearranging the endogenous immunoglobulin heavy chain variable region locus to form a rearranged non-human antibody gene.
- the non-human animal comprises a deletion of a switch sequence operably linked to an endogenous mouse heavy chain constant region.
- the switch sequence is a non-human (e.g., mouse) ⁇ switch sequence.
- the non-human animal further comprises a lack of a functional endogenous light chain variable locus selected from an immunoglobulin ⁇ locus and an immunoglobulin ⁇ locus.
- the non-human animal comprises a deletion of a J ⁇ and/or a J ⁇ sequence, such that the non-human animal is incapable of rearranging an endogenous non-human immunoglobulin ⁇ light chain and/or an endogenous non-human immunoglobulin ⁇ light chain variable region to form a rearranged endogenous non-human immunoglobulin ⁇ light chain and/or a rearranged endogenous non-human immunoglobulin ⁇ light chain gene.
- the non-human animal comprises a deletion of an endogenous non-human immunoglobulin ⁇ light chain sequence that results in a functional knockout of the endogenous non-human immunoglobulin ⁇ light chain. In one embodiment, the non-human animal comprises a deletion of an endogenous non-human immunoglobulin ⁇ light chain sequence that results in a functional knockout of the endogenous non-human immunoglobulin ⁇ light chain.
- the non-human animal comprises a functionally silenced endogenous immunoglobulin heavy chain variable gene locus, and comprises a restricted repertoire of human heavy chain variable gene segments (e.g., no more than one, or no more than two).
- the functional silencing comprises a modification of an endogenous non-human heavy chain variable gene locus selected from a deletion, an insertion, an inversion, and a combination thereof.
- a rodent in one aspect, comprises an immunoglobulin V H repertoire derived from no more than one human V H segment or one or more polymorphs thereof, from a D segment selected from a repertoire of one or more D segments, and from a J segment derived from a repertoire of one or more J segments.
- the rodent rearranges the human V H segment, a human D segment, and a human J segment and forms a rearranged human heavy chain sequence that is operably linked to a human or a rodent constant region sequence.
- the human and/or rodent constant region sequence is selected from a C H 1, a hinge, a C H 2, a C H 3, and a combination thereof.
- the rodent expresses an immunoglobulin light chain that comprises a human variable domain, wherein the light chain is cognate with a human heavy chain domain derived from the rearranged human heavy chain sequence. In one embodiment, the rodent does not express a polypeptide sequence selected from a non-human heavy chain variable domain, a non-human light chain variable domain, and a combination thereof.
- the human V H segment is present in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 or more polymorphic variants, wherein each polymorphic variant is operably linked to a D and/or J segment such that each polymorphic variant is capable for rearranging and forming a rearranged heavy chain variable domain with any of the one or more D segments and any of the one or more J segments.
- the rodent is a mouse or a rat.
- the repertoire of D segments comprises two or more D segments.
- the repertoire of J segments comprises two or more J segments.
- the D and/or J segments are human segments.
- a nucleic acid construct comprises a sequence encoding a single human immunoglobulin V H segment and/or polymorphic variants thereof and one or more D H and one or more J sequences, wherein the construct comprises at least one homology arm homologous to a non-human immunoglobulin heavy chain variable locus, or a recombinase recognition site (e.g., a lox site).
- the V segment is a V H 1-69 segment or a V H 1-2 segment.
- a nucleic acid construct comprising a nucleic acid sequence encoding a single human immunoglobulin heavy chain V segment, wherein the single V H segment is a V H 1-69 (or V H 1-2) segment.
- the construct comprises a site-specific recombinase recognition site.
- the construct comprises a first mouse homology arm upstream of the V H 1-69 (or V H 1-2) segment and a second mouse homology arm downstream of the V H 1-69 (or V H 1-2) segment, and wherein the first mouse homology arm is homologous to a region of a mouse chromosome immediately upstream of a mouse immunoglobulin heavy chain variable region but not including a functional mouse immunoglobulin heavy chain variable segment.
- the construct comprises SEQ ID NO: 3.
- the construct comprises SEQ ID NO: 70.
- the restricted single V H segment is in a non-human animal, or the restricted V H segment is at a non-human immunoglobulin heavy chain locus (e.g., in situ or in a transgene), and the non-human animal or non-human immunoglobulin heavy chain locus is selected from a mouse, rat, rabbit, pig, bovine (e.g., cow, bull, buffalo), deer, sheep, goat, chicken, cat, dog, ferret, primate (e.g., marmoset, rhesus monkey) locus or animal.
- the non-human animal or locus is a mouse or a rat locus.
- a cell or tissue wherein the cell or tissue is derived from a non-human animal as described herein, and comprises a restricted V H segment repertoire.
- the V H segment repertoire is restricted to a single V H segment family member and/or polymorphic variants thereof.
- the single V H segment is a human V H 1-69 segment or a human V H 1-2 segment.
- the cell or tissue is derived from spleen, lymph node or bone marrow of the non-human animal.
- the cell is an ES cell. In one embodiment, the cell is a B cell. In one embodiment, the cell is a germ cell.
- the tissue is selected from connective, muscle, nervous and epithelial tissue. In a specific embodiment, the tissue is reproductive tissue.
- the cell and/or tissue derived from a mouse as described herein are isolated for use in one or more ex vivo assays.
- the one or more ex vivo assays include measurements of physical, thermal, electrical, mechanical or optical properties, a surgical procedure, measurements of interactions of different tissue types, the development of imaging techniques, or a combination thereof.
- the non-human animal is a mouse.
- a non-human embryo comprising a restricted heavy chain V H segments as described herein.
- the embryo comprises an ES donor cell that comprises the restricted V H segment, and host embryo cells.
- the non-human animal is a mouse.
- a non-human cell comprising a chromosome or fragment thereof of a non-human animal as described herein.
- the non-human cell comprises a nucleus of a non-human animal as described herein.
- the non-human cell comprises the chromosome or fragment thereof as the result of a nuclear transfer.
- nucleus derived from a non-human animal as described herein is provided.
- the nucleus is from a diploid cell that is not a B cell.
- a pluripotent, induced pluripotent, or totipotent cell derived from a non-human animal as described herein is provided.
- the cell is a mouse embryonic stem (ES) cell.
- a non-human induced pluripotent cell comprising a restricted V H segment repertoire.
- the induced pluripotent cell is derived from a non-human animal as described herein.
- a hybridoma or quadroma is provided, derived from a cell of a non-human animal as described herein.
- the non-human animal is a mouse or rat.
- a lymphocyte of a non-human animal as described herein is provided.
- the lymphocyte is a B cell.
- mouse cells and mouse embryos including but not limited to ES cells, pluripotent cells, and induced pluripotent cells, that comprise genetic modifications as described herein.
- Cells that are XX and cells that are XY are provided.
- Cells that comprise a nucleus containing a modification as described herein are also provided, e.g., a modification introduced into a cell by pronuclear injection.
- an antibody variable domain sequence made in a non-human animal as described herein is provided.
- a human therapeutic comprising an antibody variable domain comprising a sequence derived from a non-human animal as described herein.
- a method of obtaining an antibody variable region sequence from a non-human animal comprising (a) immunizing a non-human animal with an antigen of interest, wherein the non-human animal comprises a replacement at the endogenous immunoglobulin heavy chain locus of all or substantially all non-human variable segments with a single human variable segment, wherein the single human variable segment is a V H 1-69 segment or a V H 1-2 segment, and wherein the non-human animal is substantially incapable of forming a immunoglobulin heavy chain variable region sequence that is not derived from a human V H 1-69 segment or a V H 1-2 segment; (b) allowing the non-human animal to mount an immune response with respect to the antigen of interest; and, (c) identifying or isolating an immunoglobulin heavy chain variable region sequence of the non-human animal, wherein the antibody binds the antigen of
- the single human variable segment is a V H 1-69 segment.
- the antibody variable region sequence is derived from SEQ ID NO: 34. In one embodiment, the antibody variable region sequence is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to SEQ ID NO: 34. In one embodiment, the antibody variable region sequence comprises SEQ ID NO: 34.
- the single human variable segment is a V H 1-2 segment.
- the antibody variable region sequence is derived from SEQ ID NO: 60. In one embodiment, the antibody variable region sequence is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical to SEQ ID NO: 60. In one embodiment, the antibody variable region sequence comprises SEQ ID NO: 60.
- the immune response to the antigen is characterized by an antibody titer that is about 6 ⁇ 10 4 to about 5 ⁇ 10 5 times greater than two times background as determined in an ELISA assay. In a specific embodiment, the antibody titer is about 1 ⁇ 10 5 to about 2 ⁇ 10 5 times greater than two times background as determined in an ELISA assay. In a specific embodiment, the antibody titer is about 1.5 ⁇ 10 5 times greater than two times background as determined in an ELISA assay. In one embodiment, the antigen is a human cell surface receptor.
- a method for generating a repertoire of human antibody variable regions in a non-human animal wherein the human heavy chain variable regions of the repertoire are derived from the same V H gene family member and one of a plurality of D H segments and one of a plurality of J H segments, wherein the repertoire is characterized by having heavy chain immunoglobulin FR1 (framework 1), CDR1, FR2, CDR2, and FR3 sequences from a single V H gene family member.
- the repertoire is further characterized by having a plurality of different CDR3+FR4 sequences.
- the single V H gene family is selected from V H family 1, 2, 3, 4, 5, 6, and 7. In a specific embodiment, the single V H gene family is V H family 1. In one embodiment, the single V H gene family member is selected from V H 1-2, V H 1-69, V H 2-26, V H 2-70, and V H 3-23. In a specific embodiment, the single V H gene family member is V H 1-69. In a specific embodiment, the single V H gene family member is V H 1-2.
- the repertoire comprises heavy chain FR1, CDR1, FR2, CDR2 and FR3 sequences derived from a V H 1-69 segment. In a specific embodiment, the repertoire comprises heavy chain FR1, CDR1, FR2, CDR2 and FR3 sequences derived from SEQ ID NO: 35. In a specific embodiment, the repertoire comprises heavy chain FR1, CDR1, FR2, CDR2 and FR3 sequences of SEQ ID NO: 35.
- the repertoire comprises heavy chain FR1, CDR1, FR2, CDR2 and FR3 sequences derived from a V H 1-2 segment. In a specific embodiment, the repertoire comprises heavy chain FR1, CDR1, FR2, CDR2 and FR3 sequences derived from SEQ ID NO: 61. In a specific embodiment, the repertoire comprises heavy chain FR1, CDR1, FR2, CDR2 and FR3 sequences of SEQ ID NO: 61.
- a biological (i.e., in vivo) system for generating a plurality of different human CDR3 sequences reflecting a plurality of rearrangements of a single human V H gene segment with a plurality of human D and J segments, wherein the system generates human heavy chain variable domains characterized by having human FR1-CDR1-FR2-CDR2-FR3 sequences that are identical but for somatic hypermutations, wherein the heavy chain variable domains are characterized by being somatically hypermutated and derived from a single human V H gene segment and a plurality of human D and J segments; wherein the system comprises a genetically modified non-human animal (e.g., a rodent, e.g., a mouse or rat) as described herein.
- a genetically modified non-human animal e.g., a rodent, e.g., a mouse or rat
- the single human V H gene segment is selected from V H 1-2, V H 1-69, V H 2-26, V H 2-70, and V H 3-23. In one embodiment, the single human V H gene segment is V H 1-69. In one embodiment, the single human V H gene segment is V H 1-2. In one embodiment, the single human V H gene segment is identified in Table 1. In one embodiment, the single human V H gene segment is identified in Table 2. In one embodiment, the single human V H gene segment is identified in Table 3.
- an in vivo method for generating a plurality of heavy chain CDR sequences derived from rearrangements of a single human V H gene segment with a plurality of human D and J segments wherein the method generates human heavy chain variable domains characterized by having human FR1-CDR1-FR2-CDR2-FR3 sequences that are identical but for somatic hypermutations, wherein the heavy chain variable domains are characterized by being somatically hypermutated and derived from a single human V H gene segment and a plurality of human D and J segments; wherein the system comprises a genetically modified non-human animal (e.g., a rodent, e.g., a mouse or rat) as described herein.
- a genetically modified non-human animal e.g., a rodent, e.g., a mouse or rat
- the method comprises exposing a non-human animal as described herein to an antigen of interest, allowing the non-human animal to develop an immune response to the antigen, wherein the immune response generates the plurality of heavy chain CDR sequences derived from rearrangements of the single human V H gene segment with one of the human D and one of the human J segments, and identifying a set of heavy chain CDRs that bind the antigen.
- the method comprises isolating from the animal a nucleic acid sequence that encodes a human V H domain that comprises the heavy chain CDRs.
- the heavy chain CDR sequences are derived from a rearrangement of a human V H 1-69 gene segment. In one embodiment, the heavy chain CDR sequences are derived from a rearrangement of a human V H 1-2 gene segment.
- a method for generating a plurality of different CDR3 and FR4 sequences in a non-human animal comprising exposing a non-human animal that comprises an immunoglobulin heavy chain variable gene locus with a V H segment repertoire restricted to a single V H segment family member to an antigen of interest, allowing the non-human animal to develop an immune response to the antigen, wherein the immune response generates a B cell repertoire whose heavy chain variable domains are each derived from the single V H segment family member and that comprise a plurality of different CDR3 and FR4 sequences.
- the singe V H segment family member is human.
- the non-human animal is selected from a mouse, a rat, and a rabbit.
- the antigen of interest is selected from a ligand, a receptor, an intracellular protein and a secreted protein.
- the antigen of interest is a human pathogen as described herein.
- the single human V H gene family member is selected from V H 1-2, V H 1-69, V H 2-26, V H 2-70, and V H 3-23. In one embodiment, the single human V H gene family member is V H 1-69. In one embodiment, the single human V H gene family member is V H 1-2. In one embodiment, the single human V H gene family member is identified in Table 1.
- the single human V H gene family member is identified in Table 2. In one embodiment, the single human V H gene family member is identified in Table 3.
- nucleotide sequence encoding an immunoglobulin variable region made in a non-human animal as described herein is provided.
- an immunoglobulin heavy chain or immunoglobulin light chain variable region amino acid sequence of an antibody made in a non-human animal as described herein is provided.
- an immunoglobulin heavy chain or immunoglobulin light chain variable region nucleotide sequence encoding a variable region of an antibody made in a non-human as described herein is provided.
- an antibody or antigen-binding fragment thereof (e.g., Fab, F(ab) 2 , scFv) made in a non-human animal as described herein is provided.
- a mouse having a restricted immunoglobulin heavy chain locus characterized by the presence of a single human V H gene segment, one or more human D H gene segments, and one or more human J H gene segments is provided, wherein the single human V H gene segment is at an endogenous mouse locus and the V H gene segment is operably linked to the one or more human D H gene segments, the one or more human J H gene segments, and to an endogenous immunoglobulin heavy chain constant gene.
- the mouse further comprises a humanized immunoglobulin light chain locus comprising one or more human V L gene segments, and one or more human J L gene segments, wherein the human V L gene segments and the human J L gene segments are operably linked to a non-human immunoglobulin light chain constant region gene.
- the human V L and J L gene segments are at an endogenous mouse light chain locus, and wherein the non-human immunoglobulin light chain constant region gene is a mouse gene.
- the humanized immunoglobulin light chain locus is on a transgene, and the constant region gene is selected from mouse, rat, and human.
- the human V L and J L gene segments are V ⁇ and J ⁇ gene segments. In one embodiment, the human V L and J L gene segments are V ⁇ and J ⁇ gene segments
- a non-human animal wherein the non-human animal has a B cell repertoire that expresses immunoglobulin heavy chain variable domains derived from a single V segment family member.
- at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90, or at least 95% of the B cell repertoire of the non-human animal immunoglobulin heavy chain variable domain expressed in the B cell repertoire is derived from the same V segment family member.
- the percentage is at least 90%.
- the B cell repertoire consists essentially of peripheral (blood) B cells.
- the B cell repertoire consists essentially of splenic B cells.
- the B cell repertoire consists essentially of bone marrow B cells.
- the B cell repertoire consists essentially of peripheral B cells, splenic B cells, and bone marrow B cells.
- a genetically modified non-human animal wherein more than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or more than 90% of the B cells of the non-human animal that express a heavy chain immunoglobulin variable domain express a heavy chain immunoglobulin variable domain derived from a single V H gene segment family member.
- at least 75% of the B cells of the non-human animal that express an immunoglobulin heavy chain variable domain express an immunoglobulin heavy chain variable domain derived from the single V H gene segment family member.
- the percentage is at least 90%.
- a genetically modified mouse makes an antigen-specific B cell population in response to immunization with an antigen of interest, wherein at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or more than 90%, of said antigen-specific B cell population expresses immunoglobulin heavy chains that are all derived from the same V H gene segment. In one embodiment, at least 75% of the antigen-specific B cell population expresses immunoglobulin heavy chains derived from the same V H gene segment. In one embodiment, all of the antigen-specific B cells express a heavy chain that is derived from the same V H gene segment.
- a non-human animal comprising a restricted V H gene segment repertoire
- the restriction is to a human V H 1-69 gene segment or a V H 1-69 gene segment that is at least about 75.5%, 76.5%, 86.7%, 87.8%, 94.9%, 96.9%, 98%, or 99% identical to a V H 1-69*01 gene segment.
- the restricted repertoire is selected from one or more of the V H 1-69 variants of FIG. 15 .
- a non-human animal comprising a restricted V H gene segment repertoire
- the restriction is to a human V H 1-2 gene segment or a V H 1-2 gene segment that is at least about 94.9%, 95.9%, 96.9%, 98%, or 99% identical to a V H 1-2 gene segment.
- the restricted repertoire is selected from one or more of the V H 1-2 variants of FIG. 18 .
- the non-human animal is a mouse.
- the mouse exhibits an immunophenotype having a characteristic of a higher ratio of mature B cells to immature B cells as compared to a wild type mouse. In a specific embodiment, the ratio is calculated from B cells harvested from spleen. In one embodiment, the mouse exhibits a population of mature B cells of about 1 ⁇ 10 7 . In one embodiment, the mouse exhibits a population of immature B cells of about 0.5 ⁇ 10 7 . In one embodiment, the mouse exhibits a ratio of mature B cells to immature B cells in the spleen of the mouse that is about 1.5-fold to about 2-fold higher than exhibited by a wild type mouse.
- the ratio is calculated from B cells harvested from bone marrow.
- the mouse exhibits a population of mature B cells of about 3 ⁇ 10 5 .
- the mouse exhibits a population of immature B cells of about 7 ⁇ 10 5 .
- the mouse exhibits a ratio of mature B cells to immature B cells in the bone marrow of the mouse that is about 3-fold, or about 3.3-fold higher than exhibited by a wild type mouse.
- the mouse exhibits an immunophenotype having a characteristic of a higher number of pro B cells in the bone marrow as compared to a wild type mouse.
- the mouse exhibits a population of pro B cells in the bone marrow of the mouse that is about 2.5-fold to about 3-fold higher than exhibited in the bone marrow of a wild type mouse.
- the mouse exhibits a population of pro B cells in the bone marrow of the mouse that is about 2.75-fold higher than exhibited in the bone marrow of a wild type mouse.
- the mouse exhibits an immunophenotype having a characteristic selected from the group consisting of a CD19 + splenic B cell population that is about 80% of a wild-type B cell, a CD3 + splenic T cell population that is about the same as a wild type mouse, and a combination thereof.
- the mouse comprises a lymphocyte population whose % CD19 + B cells in spleen are about the same as a wild-type mouse. In one embodiment, the number of CD19 + B cells per spleen of the mouse is at least about 50% of the number of CD19 + B cells per spleen of a wild-type mouse.
- the non-human animal comprises at least about 75% to about 80% of CD19 + B cells in bone marrow as compared with a wild-type mouse.
- the total number of CD19 + bone cells per femur of the mouse is non less than about 30%, 40%, 50%, 60%, or 75% of the total number of CD19+ bone marrow cells in a wild-type mouse.
- the mouse expresses IgD and IgM at about the same level as observed in a wild-type mouse.
- a mouse comprising a restricted human V H segment repertoire is provided, further comprising a humanized immunoglobulin light chain variable segment locus, wherein the ratio of ⁇ to ⁇ light chains expressed in the mouse is about the same as in a wild-type mouse.
- a mouse comprising a restricted immunoglobulin heavy chain locus characterized by the presence of a single V H gene segment, one or more D H gene segments, and one or more J H gene segments, wherein the single V H gene segment is a polymorphic V H gene segment.
- the polymorphic V H gene segment is a human V H gene segment that is associated with a high copy number in human populations.
- the human V H gene segment is selected from V H 1-2, V H 1-69, V H 2-26, V H 2-70, V H 3-23, or a polymorphic variant thereof.
- the human V H gene segment is a V H 1-69 gene segment.
- the human V H gene segment is a V H 1-2 gene segment.
- the single V H gene segment is operably linked to a human, mouse, or chimeric human/mouse immunoglobulin constant region gene.
- the immunoglobulin constant region gene is a mouse constant region gene.
- the immunoglobulin constant gene comprises a human sequence selected from a human C H 1, a human hinge, a human C H 2, a human C H 3, and a combination thereof.
- the mouse constant gene is at an endogenous immunoglobulin heavy chain locus.
- the mouse further comprises a human immunoglobulin V L gene segment operably linked to a J gene segment and a light chain constant gene.
- the V L gene segment and/or the J gene segment are selected from a human ⁇ gene segment and a human ⁇ gene segment.
- the V L and/or J gene segments are human ⁇ gene segments.
- the mouse comprises a deletion of all or substantially all endogenous V H gene segments.
- the non-human animal comprises an inactivated endogenous heavy chain variable gene locus.
- the inactivated endogenous heavy chain variable gene locus is not operably linked to an endogenous heavy chain constant region gene.
- a mouse is provided, wherein the mouse is characterized by the expression of serum immunoglobulin, wherein greater than 80% of the serum immunoglobulin comprises a human heavy chain variable domain and a cognate human light chain variable domain, wherein the human heavy chain variable domain is derived from a V H gene segment repertoire consisting essentially of a single human V H gene segment and/or polymorphic variants thereof.
- the single human V H gene segment is a human V H 1-69 gene segment and/or polymorphic variants thereof. In one embodiment, the single human V H gene segment is a human V H 1-2 gene segment and/or polymorphic variants thereof.
- a mouse comprising, in its germline, a replacement at an endogenous immunoglobulin heavy chain locus of all or substantially all endogenous V H gene segments with a single human V H gene segment and/or polymorphic variants thereof.
- the single human V H gene segment is a human V H 1-69 gene segment and/or polymorphic variants thereof.
- the single human V H gene segment is a human V H 1-2 gene segment and/or polymorphic variants thereof.
- the mouse further comprises a replacement at an endogenous immunoglobulin light chain locus of all or substantially all endogenous V L gene segments with one or more human V L gene segments.
- the mouse further comprises one or more human J L gene segments operably linked to the human V L gene segments.
- the sequence comprises a rearranged V H 1-69 gene segment. In one embodiment, the sequence comprises a rearranged V H 1-2 gene segment.
- the immunoglobulin variable region nucleotide sequence is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical with a human V H 1-69 gene segment. In a specific embodiment, the immunoglobulin variable region nucleotide sequence is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical with SEQ ID NO: 34. In various embodiments, the human V H 1-69 gene segment is identified from Table 2.
- the immunoglobulin variable region nucleotide sequence encodes an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical with SEQ ID NO: 35.
- the immunoglobulin variable region nucleotide sequence is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical with a human V H 1-2 gene segment. In a specific embodiment, the immunoglobulin variable region nucleotide sequence is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical with SEQ ID NO: 60. In various embodiments, the human V H 1-2 gene segment is identified from Table 3.
- the immunoglobulin variable region nucleotide sequence encodes an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% identical with SEQ ID NO: 61.
- the fully human Fab or fully human F(ab)2 comprises a heavy chain variable region that comprises a rearranged human V H 1-69 gene segment. In one embodiment, the fully human Fab or fully human F(ab)2 comprises a heavy chain variable region that comprises a rearranged human V H 1-2 gene segment.
- a mouse as described herein to make a phage library containing human heavy chain variable regions and human light chain variable regions is provided.
- the human heavy chain variable regions are derived from a human V H 1-69 gene segment that comprises a sequence selected from SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56 and SEQ ID NO: 58.
- the human heavy chain variable regions are derived from a human V H 1-69 gene segment that comprises a sequence selected from SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57 and SEQ ID NO: 59.
- the human heavy chain variable regions are all derived from a human V H 1-2 gene segment that comprises a sequence selected from SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66 and SEQ ID NO: 68.
- the human heavy chain variable regions are derived from a human V H 1-2 gene segment that comprises a sequence selected from SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67 and SEQ ID NO: 69.
- a mouse as described herein to generate a variable region sequence for making a human antibody comprising (a) immunizing a mouse as described herein with an antigen of interest, (b) isolating a lymphocyte from the immunized mouse of (a), (c) exposing the lymphocyte to one or more labeled antibodies, (d) identifying a lymphocyte that is capable of binding to the antigen of interest, and (e) amplifying one or more variable region nucleic acid sequence from the lymphocyte thereby generating a variable region sequence.
- the lymphocyte is derived or isolated from the spleen of the mouse. In one embodiment, the lymphocyte is derived or isolated from a lymph node of the mouse. In one embodiment, the lymphocyte is derived or isolated from the bone marrow of the mouse. In one embodiment, the lymphocyte is derived or isolated from the blood of the mouse.
- the labeled antibody is a fluorophore-conjugated antibody.
- the one or more fluorophore-conjugated antibodies are selected from an IgM, an IgG, and/or a combination thereof.
- the lymphocyte is a B cell.
- the one or more variable region nucleic acid sequence comprises a heavy chain variable region sequence. In one embodiment, the one or more variable region nucleic acid sequence comprises a light chain variable region sequence. In a specific embodiment, the light chain variable region sequence is an immunoglobulin ⁇ light chain variable region sequence. In one embodiment, the one or more variable region nucleic acid sequence comprises a heavy chain and a light chain variable region sequence.
- a mouse as described herein to generate a heavy and a ⁇ light chain variable region sequence for making a human antibody comprising (a) immunizing a mouse as described herein with an antigen of interest, (b) isolating the spleen from the immunized mouse of (a), (c) exposing B lymphocytes from the spleen to one or more labeled antibodies, (d) identifying a B lymphocyte of (c) that is capable of binding to the antigen of interest, and (e) amplifying a heavy chain variable region nucleic acid sequence and a ⁇ light chain variable region nucleic acid sequence from the B lymphocyte thereby generating the heavy chain and x light chain variable region sequences.
- a mouse as described herein to generate a heavy and a ⁇ light chain variable region sequence for making a human antibody comprising (a) immunizing a mouse as described herein with an antigen of interest, (b) isolating one or more lymph nodes from the immunized mouse of (a), (c) exposing B lymphocytes from the one or more lymph nodes to one or more labeled antibodies, (d) identifying a B lymphocyte of (c) that is capable of binding to the antigen of interest, and (e) amplifying a heavy chain variable region nucleic acid sequence and a ⁇ light chain variable region nucleic acid sequence from the B lymphocyte thereby generating the heavy chain and ⁇ light chain variable region sequences.
- a mouse as described herein to generate a heavy and a ⁇ light chain variable region sequence for making a human antibody comprising (a) immunizing a mouse as described herein with an antigen of interest, (b) isolating bone marrow from the immunized mouse of (a), (c) exposing B lymphocytes from the bone marrow to one or more labeled antibodies, (d) identifying a B lymphocyte of (c) that is capable of binding to the antigen of interest, and (e) amplifying a heavy chain variable region nucleic acid sequence and a ⁇ light chain variable region nucleic acid sequence from the B lymphocyte thereby generating the heavy chain and ⁇ light chain variable region sequences.
- the one or more labeled antibodies are selected from an IgM, an IgG, and/or a combination thereof.
- the antigen of interest is a pathogen that afflicts human subjects including, e.g., a viral antigen.
- exemplary viral pathogens include, e.g., mainly those of the families of Adenoviridae, bacteria Picornaviridae, Herpesviridae, Hepadnaviridae, Flaviviridae, Retroviridae, Orthomyxoviridae, Paramyxoviridae, Papovaviridae, Polyomavirus, Rhabdoviridae, and Togaviridae.
- Such exemplary viruses typically range between 20-300 nanometers in length.
- the antigen of interest is a viral antigen selected from a hepatitis virus (e.g., HCV, HBV, etc.), a human immunodeficiency virus (HIV), or an influenza virus (e.g., H1N1).
- a hepatitis virus e.g., HCV, HBV, etc.
- HCV human immunodeficiency virus
- H1N1 influenza virus
- use of a mouse as described herein to generate a heavy and ⁇ light chain variable region sequence for making a human antibody further comprising fusing the amplified heavy and light chain variable region sequences to human heavy and light chain constant region sequences, expressing the fused heavy and light chain sequences in a cell, and recovering the expressed heavy and light chain sequences thereby generating a human antibody.
- the human heavy chain constant regions are selected from IgM, IgD, IgA, IgE and IgG.
- the IgG is selected from an IgG1, an IgG2, an IgG3 and an IgG4.
- the human heavy chain constant region comprises a C H 1, a hinge, a C H 2, a C H 3, a C H 4, or a combination thereof.
- the light chain constant region is an immunoglobulin ⁇ constant region.
- the cell is selected from a HeLa cell, a DU145 cell, a Lncap cell, a MCF-7 cell, a MDA-MB-438 cell, a PC3 cell, a T47D cell, a THP-1 cell, a U87 cell, a SHSY5Y (human neuroblastoma) cell, a Saos-2 cell, a Vero cell, a CHO cell, a GH3 cell, a PC12 cell, a human retinal cell (e.g., a PER.C6TM cell), and a MC3T3 cell.
- the cell is a CHO cell.
- a method for generating a reverse-chimeric rodent-human antibody specific against an antigen of interest comprising the steps of immunizing a mouse as described herein with the antigen, isolating at least one cell from the mouse producing a reverse-chimeric mouse-human antibody specific against the antigen, culturing at least one cell producing the reverse-chimeric mouse-human antibody specific against the antigen, and obtaining said antibody.
- the reverse-chimeric mouse-human antibody comprises a human heavy chain variable domain fused with a mouse or rat heavy chain constant gene, and a human light chain variable domain fused with a mouse or rat or human light chain constant gene.
- the human heavy chain variable domain contains a rearranged human V H 1-69 or human V H 1-2 gene segment.
- culturing at least one cell producing the reverse-chimeric rodent-human antibody specific against the antigen is performed on at least one hybridoma cell generated from the at least one cell isolated from the mouse.
- the antigen of interest is a pathogen that afflicts human subjects as described herein.
- a method for generating a fully human antibody specific against an antigen of interest comprising the steps of immunizing a mouse as described herein with the antigen, isolating at least one cell from the mouse producing a reverse-chimeric rodent-human antibody specific against the antigen, generating at least one cell producing a fully human antibody derived from the reverse-chimeric rodent-human antibody specific against the antigen, and culturing at least one cell producing the fully human antibody, and obtaining said fully human antibody.
- the at least one cell isolated from the mouse producing a reverse-chimeric rodent-human antibody specific against the antigen is a splenocyte or a B cell.
- the antibody is a monoclonal antibody.
- the antibody comprises a heavy chain variable domain that contains a rearranged human V H 1-69 or human V H 1-2 gene segment.
- immunization with the antigen of interest is carried out with protein, DNA, a combination of DNA and protein, or cells expressing the antigen.
- the antigen of interest is a pathogen that afflicts human subjects as described herein.
- nucleic acid sequence encoding an immunoglobulin variable region or fragment thereof.
- nucleic acid sequence is used to make a human antibody or antigen-binding fragment thereof.
- the mouse is used to make an antigen-binding protein selected from an antibody, a multi-specific antibody (e.g., a bi-specific antibody), an scFv, a bi-specific scFv, a diabody, a triabody, a tetrabody, a V-NAR, a V HH , a V L , a F(ab), a F(ab) 2 , a DVD (i.e., dual variable domain antigen-binding protein), a an SVD (i.e., single variable domain antigen-binding protein), or a bispecific T-cell engager (BiTE).
- a multi-specific antibody e.g., a bi-specific antibody
- an scFv e.g., a bi-specific scFv
- a diabody e.g., a bi-specific antibody
- a triabody etrabody
- V-NAR e.g.,
- a method for making a human antigen-binding protein comprising exposing a genetically modified non-human animal as described herein to an antigen of interest, allowing the genetically modified non-human animal to mount an immune response to the antigen, obtaining from the genetically modified non-human animal a heavy chain variable domain nucleic acid sequence encoding a human heavy chain variable domain that specifically binds the antigen of interest, cloning the heavy chain variable domain nucleic acid sequence to a human constant region sequence, and expressing in a mammalian cell an antibody comprising the human heavy chain variable domain sequence and the human constant region sequence.
- the mammalian cell is a CHO cell.
- the genetically modified non-human animal comprises a human V H gene segment repertoire that consists essentially of a single human V H gene segment, optionally present in two or more polymorphic variants thereof, operably linked to one or more human D and/or J segments.
- the human V H gene segment repertoire is at an endogenous non-human V H segment locus.
- the human V H gene segment repertoire is at a locus that is not an endogenous V H segment locus.
- the human V H gene segment rearranges with a human D segment and a human J segment to form a rearranged human VDJ gene operably linked to a constant region sequence, wherein the constant region sequence is selected from a human sequence and a rodent sequence (e.g., a mouse or rat or hamster sequence).
- the constant region sequence comprises a sequence selected from a C H 1, a hinge, a C H 2, a C H 3, and a combination thereof; in a specific embodiment, the constant region sequence comprises a C H 1, a hinge, a C H 2, and a C H 3.
- the human variable domain and the constant sequence are expressed in the mammalian cell with a cognate human light chain variable domain obtained from the same mouse (e.g., sequence obtained from the same B cell as the human variable domain sequence); in one embodiment the sequence encoding the human light chain variable domain obtained from the mouse is then fused with a sequence encoding a human light chain constant sequence, and the light chain sequence and the heavy chain sequence are expressed in the mammalian cell.
- a cognate human light chain variable domain obtained from the same mouse e.g., sequence obtained from the same B cell as the human variable domain sequence
- the sequence encoding the human light chain variable domain obtained from the mouse is then fused with a sequence encoding a human light chain constant sequence, and the light chain sequence and the heavy chain sequence are expressed in the mammalian cell.
- the antigen of interest is a pathogen that afflicts human subjects as described herein.
- a method for making an antibody heavy chain variable domain that binds an antigen of interest comprising expressing in a single cell (a) a first V H sequence of an immunized non-human animal as described herein, wherein the first V H sequence is fused with a C H gene sequence; and (b) a V L gene sequence of an immunized non-human animal as described herein, wherein the V L gene sequence is fused with a human C L gene sequence; maintaining the cell under conditions sufficient to express an antibody; and, isolating the antibody heavy chain variable domain.
- the V L gene sequence is cognate with the first V H sequence.
- the cell comprises a second V H gene sequence of an immunized non-human animal as described herein, wherein the second V H gene sequence is fused with a C H gene sequence, wherein the first V H gene sequence encodes a V H domain that specifically binds a first epitope, and the second V H gene sequence encodes a V H domain that specifically binds a second epitope, wherein the first epitope and the second epitope are not identical.
- the constant region sequences are all human constant region sequences.
- the antigen of interest is a pathogen that afflicts human subjects as described herein.
- a method for making a human bispecific antibody comprising making the bispecific antibody using human variable region gene sequences of B cells of a non-human animal as described herein.
- the method comprises (a) identifying a clonally selected lymphocyte of the non-human animal, wherein the non-human animal has been exposed to an antigen of interest and allowed to develop an immune response to the antigen of interest, and wherein the lymphocyte expresses an antibody that specifically binds the antigen of interest, (b) obtaining from the lymphocyte or the antibody a nucleotide sequence that encodes a human heavy chain variable region that specifically binds the antigen of interest, and (c) employing the nucleotide sequence that encodes the human heavy chain variable region that specifically binds the antigen of interest in making the bispecific antibody.
- the human heavy chain variable region comprises a rearranged V H 1-2 or V H 1-69 gene segment.
- steps (a) through (c) are performed a first time for a first antigen of interest to generate a first human heavy chain variable region sequence
- steps (a) through (c) are performed a second time for a second antigen of interest to generate a second human heavy chain variable region sequence
- the first human heavy chain variable region sequence is expressed fused with a first human heavy chain constant region to form a first human heavy chain
- the second human heavy chain variable region sequence is expressed fused with a second human heavy chain constant region to form a second human heavy chain
- the first and the second human heavy chains are expressed in the presence of a single human light chain expressed from a rearranged human V ⁇ 1-39 or a human V ⁇ 3-20 gene segment.
- the single human light chain comprises a germline sequence.
- the method comprises (a) cloning heavy chain variable regions from B cells of a non-human animal as described herein which has been exposed to a first antigen of interest, and the same non-human animal, or a different non-human animal which is genetically the same and has been exposed to a second antigen of interest; and (b) expressing in a cell the heavy chain variable regions of (a) with the same heavy chain constant region and the same light chain to make a bispecific antibody.
- a use of a non-human animal as described herein is provided, to obtain a nucleic acid sequence that encodes a human heavy chain variable domain.
- the heavy chain variable domain comprises a rearranged human V H gene segment selected from V H 1-2 and V H 1-69.
- a use of a non-human animal as described herein is provided, to obtain a cell that encodes a human heavy chain variable domain.
- the heavy chain variable domain comprises a rearranged human V H gene segment selected from V H 1-2 and V H 1-69.
- variable domain comprises a rearranged human V H gene segment selected from V H 1-2 and V H 1-69.
- a non-human animal as described herein to make a human antibody comprising making the antibody using human variable region gene sequences of B cells of a non-human animal as described herein.
- the human antibody is a human bispecific antibody.
- the bispecific antibody comprises one heavy chain variable domain derived from a rearranged human V H 1-2 or V H 1-69 gene segment.
- the human variable region gene sequences comprise a rearranged human V H 1-2 or V H 1-69 gene segment.
- the heavy chain variable domain comprises a rearranged human V H gene segment selected from V H 1-2 and V H 1-69.
- variable sequence of a medicament comprises a polymorphic human V H gene segment.
- variable sequence of a medicament comprises a human V H 1-69 gene segment.
- variable sequence of a medicament comprises a human V H 1-2 gene segment.
- a nucleic acid construct encoding an immunoglobulin variable domain made in a mouse as described herein is provided.
- the variable domain is a heavy chain variable domain.
- the heavy chain variable domain comprises a rearranged human V H gene segment selected from V H 1-2, V H 1-69, V H 2-26, V H 2-70, or V H 3-23.
- the heavy chain variable domain comprises a rearranged human V H 1-2 gene segment.
- the heavy chain variable domain comprises a rearranged human V H 1-69 gene segment.
- variable domain is a light chain variable domain.
- variable domain is a ⁇ light chain variable domain that is cognate with a human heavy chain variable domain that comprises a rearranged human V H 1-69 gene segment.
- variable domain is a ⁇ light chain variable domain that is cognate with a human heavy chain variable domain that comprises a rearranged human V H 1-2 gene segment.
- variable domain is a light chain variable domain.
- variable domain is a ⁇ light chain variable domain that comprises a rearranged human V ⁇ gene segment selected from V ⁇ 4-1, V ⁇ 5-2, V ⁇ 7-3, V ⁇ 2-4, V ⁇ 1-5, V ⁇ 1-6, V ⁇ 3-7, V ⁇ 1-8, V ⁇ 1-9, V ⁇ 2-10, V ⁇ 3-11, V ⁇ 1-12, V ⁇ 1-13, V ⁇ 2-14, V ⁇ 3-15, V ⁇ 1-16, V ⁇ 1-17, V ⁇ 2-18, V ⁇ 2-19, V ⁇ 3-20, V ⁇ 6-21, V ⁇ 1-22, V ⁇ 1-23, V ⁇ 2-24, V ⁇ 3-25, V ⁇ 2-26, V ⁇ 1-27, V ⁇ 2-28, V ⁇ 2-29, V ⁇ 2-30, V ⁇ 3-31, V ⁇ 1-32, V ⁇ 1-33, V ⁇ 3-34, V ⁇ 1-35, V ⁇ 2-36, V ⁇ 1-37,
- variable domain is a heavy chain variable domain.
- the heavy chain variable domain comprises a rearranged human V H gene segment selected from V H 1-2, V H 1-69, V H 2-26, V H 2-70, or V H 3-23.
- the heavy chain variable domain comprises a rearranged human V H 1-69 gene segment.
- the heavy chain variable domain comprises a rearranged human V H 1-2 gene segment.
- variable domain is a light chain variable domain.
- variable domain is a ⁇ light chain variable domain that comprises a rearranged human V ⁇ gene segment selected from V ⁇ 4-1, V ⁇ 5-2, V ⁇ 7-3, V ⁇ 2-4, V ⁇ 1-5, V ⁇ 1-6, V ⁇ 3-7, V ⁇ 1-8, V ⁇ 1-9, V ⁇ 2-10, V ⁇ 3-11, V ⁇ 1-12, V ⁇ 1-13, V ⁇ 2-14, V ⁇ 3-15, V ⁇ 1-16, V ⁇ 1-17, V ⁇ 2-18, V ⁇ 2-19, V ⁇ 3-20, V ⁇ 6-21, V ⁇ 1-22, V ⁇ 1-23, V ⁇ 2-24, V ⁇ 3-25, V ⁇ 2-26, V ⁇ 1-27, V ⁇ 2-28, V ⁇ 2-29, V ⁇ 2-30, V ⁇ 3-31, V ⁇ 1-32, V ⁇ 1-33, V ⁇ 3-34, V ⁇ 1-35, V ⁇ 2-36, V ⁇ 1-37, V ⁇ 2-38, V ⁇ 1-39,
- variable domain is a heavy chain variable domain.
- the heavy chain variable domain comprises a rearranged human V H gene segment selected from V H 1-2, V H 1-69, V H 2-26, V H 2-70, or V H 3-23.
- the heavy chain variable domain comprises a rearranged human V H 1-69 gene segment.
- the heavy chain variable domain comprises a rearranged human V H 1-2 gene segment.
- the human heavy chain variable domain is characterized by having human FR1-CDR1-FR2-CDR2-FR3 sequences that are derived from a polymorphic human V H gene segment.
- the human V H gene segment is selected from a human V H 1-2, V H 1-69, V H 2-26, V H 2-70, or V H 3-23 gene segment.
- the human V H gene segment is a human V H 1-69 gene segment.
- the human V H gene segment is a human V H 1-2 gene segment.
- a method for making a nucleic acid sequence encoding a human V H domain comprising immunizing a non-human animal as described herein with an antigen of interest, allowing the non-human animal to mount an immune response to the antigen of interest, and obtaining therefrom a nucleic acid sequence encoding a human V H domain that binds the antigen of interest.
- the method further comprises making a nucleic acid sequence encoding a human V L domain that is cognate with the human V H domain, comprising isolating a B cell encoding the human V H domain and the human V L domain, and obtaining therefrom the sequence of the heavy and light chain variable domains.
- the human V H domain is derived from a rearranged human V H 1-69 or human V H 1-2 gene segment.
- the human V L domain is selected from a human V ⁇ or a human V ⁇ domain.
- variable domain is a heavy chain variable domain.
- the heavy chain variable domain is derived from a rearranged human V H 1-69 or a human V H 1-2 gene segment.
- the variable domain is a light chain variable domain.
- the light chain variable domain is derived from a rearranged human V ⁇ or human V ⁇ gene segment.
- a method for making a human therapeutic comprising immunizing a non-human animal as described herein with an antigen of interest, allowing the non-human animal to mount an immune response, and obtaining from the animal a nucleic acid sequence encoding an immunoglobulin variable domain that binds the antigen of interest, and employing the immunoglobulin variable domain in a human therapeutic.
- the variable domain is a heavy chain variable domain.
- the heavy chain variable domain is derived from a rearranged human V H 1-69 or a human V H 1-2 gene segment.
- the variable domain is a light chain variable domain.
- the light chain variable domain is derived from a rearranged human V ⁇ or human V ⁇ gene segment.
- a method for making a human antigen-binding protein comprising immunizing a non-human animal as described herein with an antigen of interest, allowing the animal to mount an immune response, obtaining from the mouse a nucleic acid sequence encoding an immunoglobulin variable domain that specifically binds the antigen of interest, cloning the nucleic acid sequence in a vector suitable for expression of the nucleic acid, wherein the nucleic acid sequence is cloned in frame with a nucleic acid sequence encoding a human immunoglobulin constant region or functional fragment thereof, and inserting the vector in a mammalian cell, and maintaining the cell under conditions suitable for expressing an antigen-binding protein that comprises the immunoglobulin variable domain and the immunoglobulin constant region or functional fragment thereof.
- the antigen-binding protein is a human antibody.
- the antibody comprises a heavy chain variable domain and a light chain variable domain obtained from a mouse as described herein.
- the antibody comprises a heavy chain variable domain obtained from a mouse as described herein.
- the heavy chain variable domain is derived from a rearranged human V H 1-69 or a human V H 1-2 gene segment.
- a nucleic acid sequence encoding a human antigen-binding domain made in a non-human animal as described herein is provided.
- the nucleic acid sequence encodes a human immunoglobulin V H domain.
- the nucleic acid sequence encodes a human immunoglobulin V H domain and a cognate human V L domain.
- the human V H domain is derived from a rearranged human V H 1-69 or a human V H 1-2 gene segment.
- a method for preparation of a human antibody comprising immunizing a non-human animal as described herein with an antigen of interest, allowing the non-human animal to mount an immune response, harvesting a lymphocyte (e.g., a B cell) from the immunized animal, fusing the lymphocyte with a myeloma cell to form a hybridoma cell, obtaining from the hybridoma cell a nucleic acid sequence that encodes a human V H domain and a human V L domain, cloning the nucleic acid sequence in frame (i.e., in operable linkage) with a human constant region sequence to create an immunoglobulin heavy chain and an immunoglobulin light chain, and expressing the heavy and light chains in a cell capable of expressing the fully human antibody.
- the cell is a CHO cell.
- the human V H domain is derived from a rearranged human V H 1-69 gene segment or a human V H 1-2 gene segment
- a method for preparation of a human antibody comprising immunizing a non-human animal as described herein with an antigen of interest, allowing the non-human animal to mount an immune response, harvesting a lymphocyte (e.g., a B cell) from the immunized animal, obtaining from the lymphocyte a nucleic acid sequence that encodes a human V H domain and a human V L domain, cloning the nucleic acid sequence in frame (i.e., in operable linkage) with a human constant region sequence to create an immunoglobulin heavy chain and an immunoglobulin light chain, and expressing the heavy and light chains in a cell capable of expressing the fully human antibody.
- a lymphocyte e.g., a B cell
- the lymphocyte is derived from the spleen of the non-human animal.
- the cell is a CHO cell.
- the human V H domain is derived from a rearranged human V H 1-69 gene segment or a human V H 1-2 gene segment.
- the antigen of interest is a pathogen that afflicts human subjects as described herein.
- the antigen of interest is a virus that is capable of infecting a human.
- Exemplary antigens that can be employed in the methods and uses described herein include microbes or microorganisms such as a virus, bacterium, prion, or fungus or any other pathogen that causes disease in humans.
- microbes or microorganisms such as a virus, bacterium, prion, or fungus or any other pathogen that causes disease in humans.
- a person of skill upon reading the disclosure, will appreciate those human pathogens that will be applicable for the methods and uses described herein.
- the various aspects and embodiments are capable of use together, unless expressly noted otherwise or the context clearly prohibits use together.
- FIG. 1 shows a general illustration, not to scale, of a series of targeting and molecular engineering steps employed to make a targeting vector for construction of a modified heavy chain locus containing a single human V H 1-69 gene segment, twenty-seven human D H and six human J H gene segments at an endogenous immunoglobulin heavy chain locus.
- FIG. 2 shows a general illustration, not to scale, of a series of targeting and molecular engineering steps employed to make a targeting vector for construction of a modified heavy chain locus containing a single human V H 1-2 gene segment, twenty-seven human D H and six human J H gene segments at an endogenous immunoglobulin heavy chain locus.
- FIG. 3 shows contour plots of splenocytes gated on single lymphocytes and stained for CD19 (B cell) and CD3 (T cell) from a wild type mouse (WT) and a mouse homozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- FIG. 4A shows, on the left, the percent of CD19 + B cells in spleens harvested from wild type mice (WT) and mice homozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- WT wild type mice
- mice homozygous for a single human V H gene segment twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- FIG. 4B shows, on the left, the percent of CD19 + B cells in bone marrow harvested from femurs of wild type mice (WT) and mice homozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- WT wild type mice
- mice homozygous for a single human V H gene segment twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- FIG. 5 shows contour plots of splenocytes gated on CD19 + B cells and stained for Ig ⁇ + and Ig ⁇ + expression from a wild type mouse (WT) and a mouse homozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- FIG. 6 shows contour plots of splenocytes gated on CD19 + B cells and stained for immunoglobulin D (IgD) and immunoglobulin M (IgM) from a wild type mouse (WT) and a mouse homozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- IgD immunoglobulin D
- IgM immunoglobulin M
- FIG. 7 shows the total number of transitional B cells (CD19 + IgM hi IgD int ), mature B cells (CD19 + IgM int IgD hi ), and the ratio of mature to immature B cells in harvested spleens from wild type mice (WT) and mice homozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- FIG. 8 shows contour plots of bone marrow gated on singlets stained for immunoglobulin M (IgM) and B220 from a wild type mouse (WT) and a mouse homozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- FIG. 9 shows the total number of immature (B220 int IgM + ) and mature (B220 hi IgM + ) B cells in bone marrow isolated from the femurs of wild type mice (WT) and mice homozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- FIG. 10 shows contour plots of bone marrow gated on CD19 + B cells and stained for ckit + and CD43 + from a wild type mouse (WT) and a mouse homozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- FIG. 11A shows the percent of CD19 + cells in populations of pro B (CD19 + CD43 + ckit + ) and pre B (CD19 + CD43 ⁇ ckit ⁇ ) cells in bone marrow harvested from the femurs of wild type mice (WT) and mice homozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- FIG. 11B shows the absolute number of cells per femur in populations of pro B (CD19 + CD43 + ckit + ) and pre B (CD19 + CD43 ⁇ ckit ⁇ ) cells in bone marrow harvested from wild type mice (WT) and mice homozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO).
- FIG. 12 shows the relative mRNA expression (y-axis) in purified splenic B cells of V H 1-69-derived heavy chains in a quantitative PCR assay using a probe specific for the human V H 1-69 gene segment in mice homozygous for a replacement of the endogenous heavy chain V H , D H , J H , and a replacement of the endogenous light chain V ⁇ and J ⁇ gene segments with human V H , D H , J H , V ⁇ and J ⁇ gene segments (H ⁇ ), wild type mice (WT), mice heterozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HET) and mice homozygous for a single human V H gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus (1hV H HO). Signals are normalized to expression of mouse C ⁇ .
- FIG. 13 shows the nucleotide alignment of the second exon for each of thirteen reported alleles for the human V H 1-69 gene. Lower case bases indicate germline nucleotide differences among the alleles. Complementary determining regions (CDRs) are indicated with boxes around the sequence. Dashes indicate artificial gaps for proper sequence alignment.
- V H 1-69*01 SEQ ID NO: 34
- V H 1-69*02 SEQ ID NO: 36
- V H 1-69*03 SEQ ID NO: 38
- V H 1-69*04 SEQ ID NO: 40
- V H 1-69*05 SEQ ID NO: 42
- V H 1-69*06 SEQ ID NO: 44
- V H 1-69*07 SEQ ID NO: 46
- V H 1-69*08 SEQ ID NO: 48
- V H 1-69*09 SEQ ID NO: 50
- V H 1-68*10 SEQ ID NO: 52
- V H 1-69*11 SEQ ID NO: 54
- V H 1-69*12 SEQ ID NO: 56
- V H 1-69*13 SEQ ID NO: 58
- FIG. 14 shows the protein alignment of the mature heavy chain variable gene sequence for each of thirteen reported alleles for the human V H 1-69 gene. Lower case amino acids indicate germline differences among the alleles. Complementary determining regions (CDRs) are indicated with boxes around the sequence. Dashes indicate artificial gaps for proper sequence alignment.
- V H 1-69*01 (SEQ ID NO: 35); V H 1-69*02 (SEQ ID NO: 37); V H 1-69*03 (SEQ ID NO: 39); V H 1-69*04 (SEQ ID NO: 41); V H 1-69*05 (SEQ ID NO: 43); V H 1-69*06 (SEQ ID NO: 45); V H 1-69*07 (SEQ ID NO: 47); V H 1-69*08 (SEQ ID NO: 49); V H 1-69*09 (SEQ ID NO: 51); V H 1-69*10 (SEQ ID NO: 53); V H 1-69*11 (SEQ ID NO: 55); V H 1-69*12 (SEQ ID NO: 57); V H 1-69*13 (SEQ ID NO: 59).
- FIG. 15 shows a percent identity/percent similarity matrix for the aligned protein sequences of the mature variable gene for each of thirteen reported alleles for the human V H 1-69 gene. Percent identity among the V H 1-69 alleles is indicated above the shaded boxes and percent similarity is indicated below the shaded boxes. Scores for percent identity and percent similarity were scored by a ClustalW (v1.83) alignment tool using MacVector software (MacVector, Inc., North Carolina).
- FIG. 16 shows the nucleotide alignment of the second exon for each of five reported alleles for the human V H 1-2 gene.
- Lower case bases indicate germline nucleotide differences among the alleles.
- Complementary determining regions (CDRs) are indicated with boxes around the sequence. Dashes indicate artificial gaps for proper sequence alignment.
- V H 1-2*01 SEQ ID NO: 60
- V H 1-2*02 SEQ ID NO: 62
- V H 1-2*03 SEQ ID NO: 64
- V H 1-2*04 SEQ ID NO: 66
- V H 1-2*05 SEQ ID NO: 68.
- FIG. 17 shows the protein alignment of the mature heavy chain variable gene sequence for each of five reported alleles for the human V H 1-2 gene. Lower case amino acids indicate germline differences among the alleles. Complementary determining regions (CDRs) are indicated with boxes around the sequence. Dashes indicate artificial gaps for proper sequence alignment. V H 1-2*01 (SEQ ID NO: 61); V H 1-2*02 (SEQ ID NO: 63); V H 1-2*03 (SEQ ID NO: 65); V H 1-2*04 (SEQ ID NO: 67); V H 1-2*05 (SEQ ID NO: 69).
- FIG. 18 shows a percent identity/percent similarity matrix for the aligned protein sequences of the mature variable gene for each of five reported alleles for the human V H 1-2 gene. Percent identity among the V H 1-2 alleles is indicated above the shaded boxes and percent similarity is indicated below the shaded boxes. Scores for percent identity and percent similarity were scored by a ClustalW (v1.83) alignment tool using MacVector software (MacVector, Inc., North Carolina).
- FIG. 21 shows the percentage (y-axis) of IgM-primed heavy chains having a specified amino acid length for the V H CDR3 region (x-axis) from mice homozygous for a single human V H 1-69 gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus and homozygous for a replacement of the endogenous ⁇ light chain variable loci with human ⁇ light chain variable loci that were immunized with a human cell surface receptor (Antigen A).
- FIG. 22 shows the percentage (y-axis) of IgG-primed heavy chains having a specified amino acid length for the V H CDR3 region (x-axis) from mice homozygous for a single human V H 1-69 gene segment, twenty-seven human D H and six human J H gene segments at the endogenous immunoglobulin heavy chain locus and homozygous for a replacement of the endogenous ⁇ light chain variable loci with human ⁇ light chain variable loci that were immunized with a human cell surface receptor (Antigen A).
- substantially all V gene segments when used to refer to an amount of gene segments (e.g., “substantially all” V gene segments) includes both functional and non functional gene segments and include, in various embodiments, e.g., 80% or more, 85% or more, 90% or more, 95% or more 96% or more, 97% or more, 98% or more, or 99% or more of all gene segments; in various embodiments, “substantially all” gene segments includes, e.g., at least 95%, 96%, 97%, 98%, or 99% of functional (i.e., non-pseudogene) gene segments.
- replacement includes wherein a DNA sequence is placed into a genome of a cell in such a way as to replace a sequence within the genome with a heterologous sequence (e.g., a human sequence in a mouse), at the locus of the genomic sequence.
- the DNA sequence so placed may include one or more regulatory sequences that are part of source DNA used to obtain the sequence so placed (e.g., promoters, enhancers, 5′- or 3′-untranslated regions, appropriate recombination signal sequences, etc.).
- the replacement is a substitution of an endogenous sequence for a heterologous sequence that results in the production of a gene product from the DNA sequence so placed (comprising the heterologous sequence), but not expression of the endogenous sequence; the replacement is of an endogenous genomic sequence with a DNA sequence that encodes a protein that has a similar function as a protein encoded by the endogenous genomic sequence (e.g., the endogenous genomic sequence encodes an immunoglobulin gene or domain, and the DNA fragment encodes one or more human immunoglobulin genes or domains).
- an endogenous gene or fragment thereof is replaced with a corresponding human gene or fragment thereof.
- a corresponding human gene or fragment thereof is a human gene or fragment that is an ortholog of, a homolog of, or is substantially identical or the same in structure and/or function, as the endogenous gene or fragment thereof that is replaced.
- V H -D H -J H variable regions of the mouse heavy chain immunoglobulin loci
- flanking mouse sequences intact and functional within the hybrid loci, including all mouse constant chain genes and locus transcriptional control regions ( FIG. 1 and FIG. 2 ).
- a single human V H , 27 D H , and six J H gene segments were introduced through chimeric BAC targeting vectors into mouse ES cells using VELOCIGENE® genetic engineering technology (see, e.g., U.S. Pat. No. 6,586,251 and Valenzuela et al., 2003, High-throughput engineering of the mouse genome coupled with high-resolution expression analysis, Nat Biotechnol 21:652-659).
- Non-human animals comprising immunoglobulin loci that comprise a restricted number of V H genes, and one or more D genes and one or more J genes, are provided, as are methods of making and using them.
- the non-human animals When immunized with an antigen of interest, the non-human animals generate B cell populations with antibody variable regions derived only from the restricted, pre-selected V H gene or set of V H genes (e.g., a pre-selected V H gene and variants thereof).
- non-human animals are provided that generate B cell populations that express human antibody variable domains that are human heavy chain variable domains, along with cognate human light chain variable domains.
- the non-human animals rearrange human heavy chain variable gene segments and human light chain variable gene segments from modified endogenous mouse immunoglobulin loci that comprise a replacement or insertion of the non-human unrearranged variable region sequences with human unrearranged variable region sequences.
- partial human immunoglobulin genes e.g., a partial repertoire of human heavy chain genes linked with a human constant gene, randomly inserted into the genome, in the presence or absence of a human light chain transgene.
- mice that express fully human immunoglobulin heavy chains derived from a single human V H 5-51 gene and 10 human D H genes and six human J H genes, with human ⁇ and ⁇ 1 constant genes, on a randomly inserted transgene (and disabled endogenous immunoglobulin loci) have been reported (Xu and Davis, 2000, Diversity in the CDR3 Region of V H Is Sufficient for Most Antibody Specificities, Immunity 13:37-45).
- the fully human immunoglobulin heavy chains of these mice are mostly expressed with one of just two fully mouse ⁇ light chains derived from the endogenous mouse ⁇ light chain locus (V ⁇ 1-J ⁇ 1 or V ⁇ 2-J ⁇ 2 only), and can express no ⁇ light chain (the mice are Ig ⁇ ⁇ / ⁇ ).
- mice exhibit severely abnormal dysfunction in B cell development and antibody expression.
- B cell numbers are reportedly 5-10% of wild-type, IgM levels 5-10% of wild-type, and IgG1 levels are only 0.1-1% of wild-type.
- the observed IgM repertoire revealed highly restricted junctional diversity.
- the fully human heavy chains display largely identical CDR3 length across antigens, the same J H (J H 2) usage across antigens, and an initial junctional Q residue, thus reflecting a certain lack of CDR3 diversity.
- the fully mouse ⁇ light chains nearly all had a W96L substitution in J ⁇ 1 as initial junctional residue.
- the mice are reportedly unable to generate any antibodies against bacterial polysaccharide. Because the human variable domains couple with mouse light chains, the utility of the human variable regions is highly limited.
- mice that have just a single human V H 3-23 gene, human D H and J H genes, and mouse light chain genes have been reported, but they exhibit a limited diversity (and thus a limited usefulness) due in part to mispairing potential between human V H and mouse V L domains (see, e.g., Mageed et al., 2001, Rearrangement of the human heavy chain variable region gene V3-23 in transgenic mice generates antibodies reactive with a range of antigens on the basis of V H CDR3 and residues intrinsic to the heavy chain variable region, Clin. Exp. Immunol. 123:1-5).
- mice that bear two V H genes (3-23 and 6-1) along with human D H and J H genes in a transgene containing the human ⁇ constant gene (Bruggemann et al., 1991, Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus, Eur. J. Immmunol. 21:1323-1326) and express them in human IgM chains with mouse light chains may exhibit a repertoire limited by mispairing (Mackworth-Young et al., 2003, The role of antigen in the selection of the human V3-23 immunoglobulin heavy chain variable region gene, Clin. Exp. Immunol. 134:420-425).
- transgenic mice that express V H -restricted fully human heavy chains from a human transgene randomly inserted in the genome, with a limited human ⁇ repertoire expressed from a fully human randomly inserted transgene, have also been reported (see, e.g., Taylor et al., 1992, A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins, Nucleic Acids Res. 20(23):6287-6295; Wagner et al., 1994, Antibodies generated form human immunoglobulin miniloci in transgenic mice, Nucleic Acids Res. 22(8):1389-1393).
- transgenic mice that express fully human antibodies from transgenes randomly integrated into the mouse genome, and that comprise damaged endogenous loci, are known to exhibit substantial differences in immune response as compared with wild-type mice that affect the diversity of the antibody variable domains obtainable from such mice.
- Useful non-human animals that generate a diverse population of B cells that express human antibody variable domains from a restricted V H gene repertoire and one or more D genes and one or more J genes will be capable of generating, preferably in some embodiments, repertoires of rearranged variable region genes that will be sufficiently diverse.
- diversity includes junctional diversity, somatic hypermutation, and polymorphic diversity in V H gene sequence (for embodiments where V H genes are present in polymorphic forms).
- Combinatorial diversity occurs in the pairing of the V H gene with one of a plurality of cognate human light chain variable domains (which, in various embodiments, comprise junctional diversity and/or somatic hypermutations).
- Non-human animals comprising a restricted human V H gene repertoire and a complete or substantially complete human V L gene repertoire will in various embodiments generate populations of B cells that reflect the various sources of diversity, such as junctional diversity (e.g., VDJ, VJ joining, P additions, N additions), combinatorial diversity (e.g., cognate V H -restricted human heavy, human light), and somatic hypermutations.
- junctional diversity e.g., VDJ, VJ joining, P additions, N additions
- combinatorial diversity e.g., cognate V H -restricted human heavy, human light
- somatic hypermutations e.g., cognate V H -restricted human heavy, human light
- the one human V H gene can be present in two or more variants.
- the presence of two or more polymorphic forms of a V H gene will enrich the diversity of the variable domains of the B cell population.
- Variations in the germline sequences of gene segments contribute to the diversity of the antibody response in humans.
- the relative contribution to diversity due to V gene sequence differences varies among V genes.
- the degree of polymorphism varies across gene families, and is reflected in a plurality of haplotypes (stretches of sequence with coinherited polymorphisms) capable of generating further diversity as observed in V H haplotype differences between related and unrelated individuals in the human population (see, e.g., Souroujon et al., 1989, Polymorphisms in Human H Chain V Region Genes from the V H III Gene Family, J. Immunol. 143(2):706-711).
- V H polymorphism can be described in two principle forms. The first is variation arising from allelic variation associated with differences among the nucleotide sequence between alleles of the same gene segment. The second arises from the numerous duplications, insertions, and/or deletions that have occurred at the immunoglobulin heavy chain locus. This has resulted in the unique situation in which V H genes derived by duplication from identical genes differ from their respective alleles by one or more nucleotide substitutions. This also directly influences the copy number of V H genes at the heavy chain locus.
- V H genes Polymorphic alleles of the human immunoglobulin heavy chain variable gene segments (V H genes) have largely been the result of insertion/deletion of gene segments and single nucleotide differences within coding regions, both of which have the potential to have functional consequences on the immunoglobulin molecule.
- Table 1 sets forth the functional V H genes listed by human V H gene family and the number of identified alleles for each V H gene in the human immunoglobulin heavy chain locus. There are some findings to suggest that polymorphic V H genes have been implicated in susceptibility to certain diseases such as, for example, rheumatoid arthritis, whereas in other cases a linkage between V H and disease has been less clear.
- humanized mice as described herein with restricted V H repertoires comprise multiple polymorphic variants of an individual V H family member (e.g., two or more polymorphic variants of V H 1-2, V H 1-69, V H 2-26, V H 2-70, or V H 3-23, replacing all or substantially all functional mouse V H segments at an endogenous mouse locus).
- the two or more polymorphic variants of mice described herein are in number up to and including the number indicated for the corresponding V H family member in Table 1 (e.g., for V H 1-69, 13 variants; for V H 1-2, five variants; etc.).
- V H 1-69 genes are known in the art.
- the human V H 1-69 gene has 13 reported alleles (Sasso et al., 1993, A fetally expressed immunoglobulin V H 1 gene belongs to a complex set of alleles, Journal of Clinical Investigation 91:2358-2367; Sasso et al., 1996, Expression of the immunoglobulin V H gene 51p1 is proportional to its germline gene copy number, Journal of Clinical Investigation 97(9):2074-2080) and exists in at least three haplotypes that carry duplications of the V H 1-69 gene, which results in multiple copies of the V H gene at a given locus.
- CDRs complementarity determining regions
- Representative genomic DNA and full-length protein sequences of a V H 1-69 gene are set forth in SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
- FIG. 13 and FIG. 14 set forth DNA and protein alignments of thirteen reported V H 1-69 alleles, respectively.
- Representative DNA and protein sequences of a V H 1-2 gene are set forth in SEQ ID NO: 60 and SEQ ID NO: 61, respectively.
- FIG. 16 and FIG. 17 set forth DNA and protein alignments of five reported V H 1-2 alleles, respectively.
- FIG. 15 and FIG. 18 set forth a percent identity/similarity matrix for aligned protein sequences corresponding to thirteen reported human V H 1-69 alleles and five reported human V H 1-2 alleles, respectively.
- the modified locus of the invention comprises a V H gene selected from Table 1, present in two or more copy number, wherein the copy number includes up to and including the number of alleles shown in Table 1.
- the modified locus of the invention comprises a V H 1-69 gene selected from Table 2, present in two or more copy number, wherein the copy number includes up to and including the number of alleles shown in Table 1.
- the modified locus of the invention comprises a V H 1-2 gene selected from Table 3, present in two or more copy number, wherein the copy number includes up to and including the number of alleles shown in Table 1.
- non-human animals that express a restricted human V H repertoire are also provided.
- Such non-human animals include any of those which can be genetically modified to express a restricted human V H repertoire as disclosed herein, including, e.g., mouse, rat, rabbit, pig, bovine (e.g., cow, bull, buffalo), deer, sheep, goat, chicken, cat, dog, ferret, primate (e.g., marmoset, rhesus monkey), etc.
- suitable genetically modifiable ES cells are not readily available, other methods are employed to make a non-human animal comprising the genetic modification.
- Such methods include, e.g., modifying a non-ES cell genome (e.g., a fibroblast or an induced pluripotent cell) and employing nuclear transfer to transfer the modified genome to a suitable cell, e.g., an oocyte, and gestating the modified cell (e.g., the modified oocyte) in a non-human animal under suitable conditions to form an embryo.
- a suitable cell e.g., an oocyte
- Methods for modifying a non-human animal genome include, e.g., employing a zinc finger nuclease (ZFN) or a transcription activator-like effector nuclease (TALEN) to modify a genome to include a restricted human V H repertoire.
- ZFN zinc finger nuclease
- TALEN transcription activator-like effector nuclease
- a method for editing a non-human animal genome to include a restricted human V H repertoire comprising a step of editing the genome employing a ZFN or a TALEN to include no more than one, or no more than two, human V H gene segments (or polymorphic variants thereof), wherein the no more than one or no more than two human V H gene segments are operably linked to an immunoglobulin constant gene sequence.
- the constant gene sequence is selected from a human heavy chain constant sequence and a non-human heavy chain constant sequence.
- the constant sequence is non-human and the no more than one or no more than two human V H gene segments are operably linked to non-human constant gene sequence at an endogenous non-human immunoglobulin locus.
- the non-human animal is a small mammal, e.g., of the superfamily Dipodoidea or Muroidea.
- the genetically modified animal is a rodent.
- the rodent is selected from a mouse, a rat, and a hamster.
- the rodent is selected from the superfamily Muroidea.
- the genetically modified animal is from a family selected from Calomyscidae (e.g., mouse-like hamsters), Cricetidae (e.g., hamster, New World rats and mice, voles), Muridae (true mice and rats, gerbils, spiny mice, crested rats), Nesomyidae (climbing mice, rock mice, with-tailed rats, Malagasy rats and mice), Platacanthomyidae (e.g., spiny dormice), and Spalacidae (e.g., mole rates, bamboo rats, and zokors).
- Calomyscidae e.g., mouse-like hamsters
- Cricetidae e.g., hamster, New World rats and mice, voles
- Muridae true mice and rats, gerbils, spiny mice, crested rats
- Nesomyidae climbing mice, rock mice, with
- the genetically modified rodent is selected from a true mouse or rat (family Muridae), a gerbil, a spiny mouse, and a crested rat.
- the genetically modified mouse is from a member of the family Muridae,
- the non-human animal is a rodent that is a mouse of a C57BL strain.
- the C57BL strain is selected from C57BL/A, C57BL/An, C57BL/GrFa, C57BL/KaLwN, C57BL/6, C57BL/6J, C57BL/6ByJ, C57BL/6N, C57BL/6NJ, C57BL/10, C57BL/10ScSn, C57BL/10Cr, and C57BL/Ola.
- the mouse is a 129 strain.
- the 129 strain is selected from the group consisting of 129P1, 129P2, 129P3, 129X1, 129S1 (e.g., 129S1/SV, 129S1/SvIm), 129S2, 129S4, 129S5, 129S9/SvEvH, 129S6 (129/SvEvTac), 129S7, 129S8, 129T1, 129T2 (see, e.g., Festing et al. (1999) Revised nomenclature for strain 129 mice, Mammalian Genome 10:836, see also, Auerbach et al.
- the genetically modified mouse is a mix of an aforementioned 129 strain and an aforementioned C57BL strain (e.g., a C57BL/6 strain).
- the mouse is a mix of aforementioned 129 strains, or a mix of aforementioned C57BL/6 strains.
- the 129 strain of the mix is a 129S6 (129/SvEvTac) strain.
- the mouse is a mix of a 129/SvEv- and a C57BL/6-derived strain.
- the mouse is a mix of a 129/SvEv- and a C57BL/6-derived strain as described in Auerbach et al. 2000 BioTechniques 29:1024-1032.
- the mouse is a BALB strain, e.g., BALB/c strain.
- the mouse is a mix of a BALB strain (e.g., BALB/c strain) and another aforementioned strain.
- the non-human animal is a rat.
- the rat is selected from a Wistar rat, an LEA strain, a Sprague Dawley strain, a Fischer strain, F344, F6, and Dark Agouti.
- the rat strain is a mix of two or more of a strain selected from the group consisting of Wistar, LEA, Sprague Dawley, Fischer, F344, F6, and Dark Agouti.
- IgHV1-69 Accession SEQ ID NO: Allele Number (DNA/Protein) IgHV1-69*01 L22582 34/35 IgHV1-69*02 Z27506 36/37 IgHV1-69*03 X92340 38/39 IgHV1-69*04 M83132 40/41 IgHV1-69*05 X67905 42/43 IgHV1-69*06 L22583 44/45 IgHV1-69*07 Z29978 46/47 IgHV1-69*08 Z14309 48/49 IgHV1-69*09 Z14307 50/51 IgHV1-69*10 Z14300 52/53 IgHV1-69*11 Z14296 54/55 IgHV1-69*12 Z14301 56/57 IgHV1-69*13 Z14214 58/59
- IgHV1-2 Accession SEQ ID NO: Allele Number (DNA/Protein) IgHV1-2*01 X07448 60/61 IgHV1-2*02 X62106 62/63 IgHV1-2*03 X92208 64/65 IgHV1-2*04 Z12310 66/67 IgHV1-2*05 HM855674 68/69 Antigen-Dependent V H Gene Usage
- V H genes Antigen-dependent preferential usage of V H genes can be exploited in the development of human therapeutics targeting clinically significant antigens.
- the ability to generate a repertoire of antibody variable domains using a particular V H gene can provide a significant advantage in the search for high-affinity antibody variable domains to use in human therapeutics.
- Studies on naive mouse and human V H gene usage in antibody variable domains reveal that most heavy chain variable domains are not derived from any particular single or dominantly used V H gene.
- studies of antibody response to certain antigens reveal that in some cases a particular antibody response displays a biased usage of a particular V H gene in the B cell repertoire following immunization.
- V H usage in peripheral B cells in humans is skewed.
- functional V gene abundance followed the pattern V H 3>V H 4>V H 1>V H 2>V H 5>V H 6 (Davidkova et al., 1997, Selective Usage of V H Genes in Adult Human Lymphocyte Repertoires, Scand. J. Immunol.
- V H 3 family usage frequency was about 0.65
- V H 1 family usage frequency was about 0.15; these and other observations suggest that the germline complexity of the human V H repertoire is not precisely reflected in the peripheral B cell compartment in humans that have a normal germline V H repertoire, a situation that is similar to that observed in the mouse—i.e., V H gene expression is non-stochastic (Zouali and These, 1991, Probing V H Gene-Family Utilization in Human Peripheral B Cells by In Situ Hybridization, J. Immunol. 146(8):2855-2864).
- V H gene usage in humans is V H 3>V H 4>V H 1>V H 5>V H 2>V H 6; rearrangements in peripheral B cells reveal that V H 3 family usage is higher than to be expected based on the relative number of germline V H 3 genes (Brezinschek et al., 1995).
- V H usage in humans follows the pattern V H 3>V H 5>V H 2>V H 1>V H 4>V H 6, based on analysis of pokeweed mitogen-activated peripheral small immunocompetent B cells (Davidkova et al., 1997, Selective Usage of V H Genes in Adult Human B Lymphocyte Repertoires, Scand. J. Immunol.
- V H 3 family members are 3-23, 3-30 and 3-54 (Brezinschek et al., 1995).
- member 4-59 and 4-4-b were found relatively more frequently (Id.), as well as 4-39 and 4-34 (Brezinscheck et al., 1997, Analysis of the Human V H Gene Repertoire, J. Clin. Invest. 99(10):2488-2501).
- V H 4-59 the most commonly used V H gene in the adult human repertoire is V H 4-59, followed by V H 3-23 and V H 3-48 (Arnaout of al., 2001, High-Resolution Description of Antibody Heavy-Chain Repertoires in Humans, PLoS ONE 6(8):108).
- usage studies are based on relatively small sample numbers and thus exhibit high variance, taken together the studies suggest that V gene expression is not purely stochastic. Indeed, studies with particular antigens have established that—in certain cases—the deck is firmly stacked against certain usages and in favor of others.
- V H 1-69-derived heavy chains have been observed in a variety of antigen-specific antibody repertoires of therapeutic significance. For instance, V H 1-69 was frequently observed in heavy chain transcripts of an IgE repertoire of peripheral blood lymphocytes in young children with atopic disease (Bando et al., 2004, Characterization of V H ⁇ gene expressed in PBL from children with atopic diseases: detection of homologous V H 1-69 derived transcripts from three unrelated patients, Immunology Letters 94:99-106).
- V H 1-69-derived heavy chains with a high degree of somatic hypermutation also occur in B cell lymphomas (Perez of al., 2009, Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of V H 1-69 and V H 4-59 segments, British Journal of Dermatology 162:611-618), whereas some V H 1-69-derived heavy chains with essentially germline sequences (i.e., little to no somatic hypermutation) have been observed among autoantibodies in patients with blood disorders (Pos et al., 2008, V H 1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura, Journal of Thrombosis and Haemostasis 7:421-428).
- V H 1-69-derived sequences (Miklos of al., 2000, Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V H genes show frequent use of V1-69 with distinctive CDR3 features, Blood 95(12):3878-3884; Kunert et al., 2004, Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type I neutralizing monoclonal antibody, Aids Research and Human Retroviruses 20(7):755-762; Chan et al., 2001, V H 1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen, Blood 97(4):1023-1026; Carbonari et al., 2005
- V H usage bias is also observed in the humoral immune response to Haemophilus influenzae type b (Hib PS) in humans.
- the V H III family (the V H IIIb subfamily in particular, V H 9.1) exclusively characterizes the human humoral response to Hib PS, with diverse D and J genes (Adderson et al., 1991, Restricted Ig H Chain V Gene Usage in the Human Antibody Response to Haemophilus influenzae Type b Capsular Polysaccharide, J. Immunol. 147(5):1667-1674; Adderson et al., 1993, Restricted Immunoglobulin V H Usage and VDJ Combinations in the Human Response to Haemophilus influenzae Type b Capsular Polysaccharide, J. Clin. Invest. 91:2734-2743).
- Human J H genes also display biased usage; J H 4 and J H 6 are observed at about 38-41% in peripheral B cells in humans (Brezinschek et al., 1995).
- V H usage in HIV-1-infected humans is reportedly biased against V H 3 usage and in favor of V H 1 and V H 4 gene families (Wisnewski et al., 1996, Human Antibody Variable Region Gene Usage in HIV-1 Infection, J. Acquired Immune Deficiency Syndromes & Human Retroviology 11(1):31-38).
- cDNA analysis of bone marrow from affected patients' revealed significant V H 3 usage not expressed in the functional B cell repertoire, where Fabs reflecting the V H 3 usage exhibited effective in vitro neutralization of HIV-1 (Id.).
- modified non-human animals as described herein might thus be useful for generating neutralizing antibody domains derived from particular V H genes present in the genetically modified animals described herein, but derived from different V H genes than those observed in the restricted repertoire of affected humans.
- V H -restricted mice e.g., (restricted, e.g., to a V H 3 family member and polymorph(s) thereof) immunized with HIV-1
- restricted e.g., restricted to a V H 3 family member or variant(s) thereof
- Restriction of the human antibody response to certain pathogens may reduce the likelihood of obtaining antibody variable regions from affected humans that can serve as springboards for designing high affinity neutralizing antibodies against the pathogen.
- the human immune response to HIV-1 infection is clonally restricted throughout HIV-1 infection and into AIDS progression (Muller et al., 1993, B-cell abnormalities in AIDS: stable and clonally restricted antibody response in HIV-1 infection, Scand. J. Immunol. 38:327-334; Wisnewski et al., 1996).
- V H genes are in general not present in all polymorphic forms in any particular individual; certain individuals in certain populations possess one variant, whereas individuals in other populations possess a different variant.
- a genetically modified non-human animal that comprises a plurality of polymorphic variants of no more than one, or no more than two, human V H gene segment family member.
- the no more than one, or no more than two, human V H gene segments are operably linked to one or more human D H gene segments, one or more human J H gene segments, and a human or non-human constant region gene segment.
- the constant region is at an endogenous non-human immunoglobulin constant gene locus.
- the non-human animal further comprises a nucleic acid sequence derived from a human V L sequence, e.g., a rearranged or unrearranged human V L gene segment or a rearranged human V L /J L sequence.
- the nucleic acid sequence derived from the human V L sequence is at an endogenous non-human V L gene locus; in one embodiment, the nucleic acid sequence derived form the human V L sequence is on a transgene.
- the non-human animal is incapable of expressing an immunoglobulin light chain variable domain that itself comprises an endogenous V L or J L gene segment, and comprises no more than one, or no more than two, light chain genes that encode rearranged human V L domains (i.e., from no more than one, or no more than two, rearranged human V L /J L sequences).
- a restricted repertoire in one embodiment, refers to a predetermined limitation in the number and/or identity of germline genes that results in the mouse being unable to form a rearranged heavy chain gene that is derived from any V gene other than a preselected V gene.
- the repertoire is restricted with respect to the identity of the V gene but not the D and/or J gene (e.g., the repertoire consists essentially of no more than one, or no more than two, V H gene segments (and/or polymorphs thereof); and a plurality of D gene segments and a plurality of J gene segments)).
- the identity of the preselected V gene (and any preselected D and/or J genes) is not limited to any particular V gene.
- V H gene present as a single segment or a set of variants
- D H and J H segments e.g., D H and J H segments
- an in vivo junctional diversity/combinatorial diversity/somatic hypermutation permutation machine that can be used to iterate mutations in resulting rearranged heavy chain variable region sequences (e.g., V/D/J or V/J, as the case may be).
- the clonal selection process operates to select suitable variable regions that bind an antigen of interest that are based on a single preselected V H gene (or variants thereof).
- the mouse's clonal selection components are dedicated to selection based on the single preselected V H gene segment, background noise (e.g., a wide variety of non antigen-binding V H domains derived from many germline gene segments) is largely eradicated.
- background noise e.g., a wide variety of non antigen-binding V H domains derived from many germline gene segments
- judicious selection of the V H gene segment a relatively larger number of clonally selected, antigen-specific antibodies can be screened in a shorter period of time than with a mouse with a large diversity of V segments.
- Preselecting limited repertoire and restricting a mouse to a single V segment provides a system for permuting V/D/J junctions at a rate that is in various embodiments higher than that observed in mice that otherwise have up to 40 or more V segments to recombine with D and J regions. Removal of other V segments frees the locus to form more V/D/J combinations for the preselected V segment than otherwise observed.
- the increased number of transcripts that result from the recombination of the preselected V with one of a plurality of D and one of a plurality of J segments will feed those transcripts into the clonal selection system in the form of pre-B cells, and the clonal selection system is thus dedicated to cycling B cells that express the preselected V region. In this way, more unique V region rearrangements derived from the preselected V segment can be screened by the organism than would otherwise be possible in a given amount of time.
- mice are described that enhance the junctional diversity of V/D/J recombinations for the preselected V region, because all or substantially all recombinations of the immunoglobulin heavy chain variable locus will be of the preselected V segment and the D and J segments that are placed in such mice. Therefore, the mice provide a method for generating a diversity of CDR3 segments using a base, or restricted V H gene repertoire.
- a non-human animal wherein the B cell population of the non-human animal expresses immunoglobulin heavy chains that are derived from no more than one, or no more than two human V H gene segments.
- each of the no more than one, or no more than two, human V H gene segments are present in two or more polymorphic forms.
- the human V H gene segment is present in three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 polymorphic forms.
- the non-human animal expresses a human light chain variable domain derived from a human V L gene segment.
- a method for generating a B cell population in a non-human animal, wherein the B cell population expresses human heavy chains derived from a single germline human V H gene segment and two or more human D gene segments and two or more human J gene segments; the method comprising a step of immunizing a non-human animal as described herein with an antigen of interest, and allowing the non-human animal to mount an immune response to the antigen of interest, wherein the immune response comprises expressing the human heavy chains on the surface of B cells in the B cell population
- the non-human animal is a rodent (e.g., a mouse or rat).
- the human V H gene segment, human D H segment, and human J H segment are operably linked to a non-human constant region gene.
- the non-human animal further comprises a nucleic acid sequence encoding a human V L domain.
- the nucleic acid sequence encoding the human V L domain is linked to a non-human light chain constant region gene sequence.
- a method for making a non-human animal that expresses an immunoglobulin population characterized by the immunoglobulins having heavy chains that are derived from a plurality of rearrangements of a single human V H gene segment (or sing human V H gene family member) and one of a plurality of D H gene segments and one of a plurality of J H gene segments is provided.
- the human V H gene segment is a human V H 1-69 gene segment.
- the human V H gene segment is a human V H 1-2 gene segment.
- a method for generating a population of human immunoglobulin heavy chain variable domains whose CDR1 and CDR2 are derived from the same germline V H gene segment, and whose CDR3 are derived from the germline gene segment and two or more human D segments, and two or more human J segments; the method comprising immunizing a non-human animal as described herein with an antigen of interest, and allowing the non-human animal to mount an immune response to the antigen of interest, wherein the immune response comprises expressing the human heavy chain variable domains in the context of a light chain variable domain.
- the non-human animal is a rodent (e.g., a mouse or rat).
- the human V H gene segment, human D segment, and human J segment are operably linked to a non-human constant region gene.
- the non-human animal further comprises a nucleic acid sequence encoding a human V L domain.
- the nucleic acid sequence encoding the human V L domain is linked to a non-human light chain constant region gene sequence.
- a genetically modified non-human animal wherein the non-human animal is incapable of expressing a non-human V H domain, and wherein each immunoglobulin heavy chain of the heavy chain population expressed in the animal comprises a human V H domain comprising a CDR1 and a CDR2 that are identical but for one or more somatic hypermutations, and wherein the heavy chain population comprises a plurality of CDR3 sequences derived from a plurality of rearrangements with a plurality of D and J gene segments.
- a biological system for generating variation in CDR3 identity and length comprising a genetically modified non-human animal as described herein, wherein the non-human animal comprises no more than or no more than two human V H gene segments, and two or more D gene segments and one or more J gene segments, wherein the non-human animal further comprises a humanized immunoglobulin light chain locus.
- the non-human animal in response to immunization with an antigen of interest generates an immune response that comprises expressing an immunoglobulin heavy chain population characterized by each heavy chain having CDR1s and CDR2s that differ only by somatic hypermutation, and CDR3s that differ by rearrangement and somatic hypermutation.
- the biological system is a mouse that is genetically modified as described herein.
- the human V H gene segment and the human V L gene segment are at endogenous mouse heavy and light immunoglobulin loci, respectively.
- one or more of the human V H gene segment and the human V L gene segment are on transgenes (i.e., at a locus other than an endogenous immunoglobulin locus).
- a uniquely engineered human heavy chain locus containing a single human V H gene segment located upstream of all the human D H and J H gene segments was created by a series of homologous recombination reactions in bacterial cells (BHR) using Bacterial Artificial Chromosome (BAC) DNA.
- BHR Bacterial Artificial Chromosome
- BAC Bacterial Artificial Chromosome
- Several targeting constructs for creation of a single V H containing heavy chain locus were constructed using VELOCIGENE® genetic engineering technology (see, e.g., U.S. Pat. No. 6,586,251 and Valenzuela, D. M. et al. (2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nature Biotechnology 21(6): 652-659).
- a modified human BAC containing multiple distal (5′) human V H gene segments, including V H 1-69, an upstream hygromycin selection cassette and a 5′ mouse homology arm was targeted with a second spectinomycin cassette, which also contained a modified recombination signal sequence (RSS; BHR 1, FIG. 1 , top left).
- This modified recombination signal sequence (RSS) introduced two point mutations (T to A and G to A) in the 3′ RSS region of the human V H 1-69 gene changing the RSS nonamer to the optimal consensus sequence.
- the first modification created a human genomic fragment containing the human V H 1-69 gene segment with a modified 3′ RSS, a unique AsiSI restriction site about 180 bp downstream of the RSS and a spectinomycin cassette ( FIG. 1 , middle left).
- the second modification (BHR 2) included the use of a neomycin (Neo) cassette flanked by Frt sites to delete the hygromycin cassette and 5′ human V H gene segments upstream of the V H 1-69 gene segment. This modification was targeted 5′ to the human V H 1-69 gene segment to leave intact about 8.2 kb of the promoter region of human V H 1-69 and the 5′ mouse homology arm ( FIG. 1 , bottom left).
- Neo neomycin
- the third modification (BHR 3) included another spectinomycin cassette flanked by uniquely engineered 5′ PI-SceI and 3′ AsiSI sites targeted to a human genomic fragment containing the first three functional human V H gene segments and all the human D H and J H gene segments ( FIG. 1 , middle right).
- the human genomic fragment was previously targeted with a neomycin cassette and contained 5′ and 3′ homology arms containing the mouse genomic sequence 5′ and 3′ of the endogenous heavy chain locus including the 3′ intronic enhancer and the IgM gene.
- This modification deleted the 5′ mouse genomic sequence and human V H gene segments, leaving about 3.3 kb of the V H -D H intergenic region upstream of the human D H 1-1 gene segment, all of the human D H and J H segments, and the 3′ mouse genomic fragment containing the 3′ intronic enhancer and the IgM gene ( FIG. 1 , bottom right).
- the fourth modification was achieved by employing the unique PI-SceI and AsiSI sites (described above) to ligate the two modified BACs from BHR 2 and BHR 3 ( FIG. 1 , bottom center), which yielded the final targeting construct.
- the final targeting construct for the creation of a modified heavy chain locus containing a single human V H gene segment and all the human D H and J H gene segments in ES cells contained, from 5′ to 3′, a 5′ homology arm containing about 20 kb of mouse genomic sequence upstream of the endogenous heavy chain locus, a 5′ Frt site, a neomycin cassette, a 3′ Frt site, about 8.2 kb of the human V H 1-69 promoter, the human V H 1-69 gene segment with a modified 3′ RSS, 27 human D H gene segments, six human J H segments, and a 3′ homology arm containing about 8 kb of mouse genomic sequence downstream of the mouse J H gene segments including the 3′ intronic enhancer and IgM gene
- V H gene segments in the context of mouse heavy chain constant regions are employed to construct a series of mice having a restricted number immunoglobulin heavy chain V segments (e.g., 1, 2, 3, 4, or 5), wherein the V segments are polymorphic variants of a V gene family member.
- exemplary polymorphic V H gene segments are derived from human V H gene segments including, e.g., V H 1-2, V H 2-26, V H 2-70 and V H 3-23.
- Such human V H gene segments are obtained, e.g., by de novo synthesis (e.g., Blue Heron Biotechnology, Bothell, Wash.) using sequences available on published databases.
- DNA fragments encoding each V H gene are, in some embodiments, generated independently for incorporation into targeting vectors, as described herein.
- multiple modified immunoglobulin heavy chain loci comprising a restricted number of V H gene segments are engineered in the context of mouse heavy chain constant regions.
- An exemplary targeting strategy for creating a restricted humanized heavy chain locus containing a human V H 1-2 gene segment, 27 human D H gene segments, and six human J H gene segments is shown in FIG. 2 .
- a modified human BAC clone containing three human V H gene segments (V H 6-1, V H 1-2, V H 1-3), 27 human D H gene segments, and six human J H gene segments (see U.S. Ser. No. 13/404,075; filed 24 Feb. 2012, herein incorporated by reference) is used to create a restricted humanized heavy chain locus containing a human V H 1-2 gene segment.
- This modified BAC clone functionally links the aforementioned human heavy chain gene segments with the mouse intronic enhancer and the IgM constant region.
- the restricted human V H 1-2 based heavy chain locus is achieved by two homologous recombinations using the modified human BAC clone described above.
- 205 bp of the human V H 6-1 gene segment (from about 10 bp upstream (5′) of the V H 6-1 start codon in exon 1 to about 63 bp downstream (3′) of the beginning of exon 2) in the modified human BAC clone is deleted by bacterial homologous recombination using a spectinomycin (aadA) cassette flanked by unique PI-SceI restriction sites ( FIG. 2 , BHR 1). This allows for subsequent removal of the aadA cassette without disrupting other human gene segments within the restricted heavy chain locus.
- aadA spectinomycin
- the 5′ end of the modified human BAC clone including the entire human V H 1-3 gene segment and about 60 bp downstream (3′) of the gene segment is deleted by homologous recombination using a hygromycin cassette containing flanking 5′ AsiSI and 3′ AscI restriction sites ( FIG. 2 , BHR 2).
- the spectinomycin cassette is optionally removed after confirmation of the final targeting vector including deletion of the two human V H gene segments flanking the human V H 1-2 gene segment ( FIG. 2 , bottom).
- An exemplary human V H 1-2 targeting vector is set forth in SEQ ID NO: 70.
- V H gene segments in a restricted immunoglobulin heavy chain locus represents a novel approach for generating antibodies, populations of antibodies, and populations of B cells that express antibodies having heavy chains with diverse CDRs derived from a single human V H gene segment.
- Exploiting the somatic hypermutation machinery of the host animal along with combinatorial association with rearranged human immunoglobulin light chain variable domains results in the engineering of unique heavy chains and unique V H /V L pairs that expand the immune repertoire of genetically modified animals and enhance their usefulness as a next generation platform for making human therapeutics, especially useful as a platform for making neutralizing antibodies specific for human pathogens.
- Targeted ES cells described above were used as donor ES cells and introduced into an 8-cell stage mouse embryo by the VELOCIMOUSE® method (supra).
- Mice bearing a humanized heavy chain locus containing a single human V H gene segment, all the human D H and J H gene segments operably linked to the mouse immunoglobulin constant region genes were identified by genotyping using a modification of allele assay (Valenzuela et al., supra) that detected the presence of the neomycin cassette, the human V H gene segment and a region within the human D H and J H gene segments as well as endogenous heavy chain sequences.
- Table 4 sets forth the primers and probes used in this assay to confirm mice harboring a restricted heavy chain locus containing a single human V H 1-69 gene segment, 27 human D H gene segments and six human J H gene segments.
- mice bearing an engineered heavy chain locus that contains a single human V H gene segment can be bred to a FLPe deletor mouse strain (see, e.g., Rodriguez, C. I. et al. (2000) High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nature Genetics 25: 139-140) in order to remove any Frt'ed neomycin cassette introduced by the targeting vector that is not removed, e.g., at the ES cell stage or in the embryo. Optionally, the neomycin cassette is retained in the mice.
- Pups are genotyped and a pup heterozygous for a humanized heavy chain locus containing a single human V H gene segment, all the human D H and J H segments operably linked to the endogenous mouse immunoglobulin constant genes is selected for characterizing the immunoglobulin heavy chain repertoire.
- mice homozygous for a single human V H gene segment at the endogenous heavy chain locus as described in Example 1 were evaluated for expression and B cell development using flow cytometry.
- Red blood cells from spleens were lysed with ACK lysis buffer (Lonza Walkersville), followed by washing with complete RPMI medium.
- Bone marrow panel anti-mouse FITC-CD43 (1B11, BioLegend), PE-ckit (2B8, BIOLEGEND®), PeCy7-IgM (II/41, EBIOSCIENCE®), PerCP-Cy5.5-IgD (11-26c.2a, BIOLEGEND®), APC-eFluor 780-B220 (RA3-6B2, EBIOSCIENCE®), APC-CD19 (MB19-1, EBIOSCIENCE®).
- Bone marrow and spleen panel anti-mouse FITC-Ig ⁇ (187.1, BD Biosciences), PE-Ig ⁇ (RML-42, BIOLEGEND®), PeCy7-IgM (II/41, EBIOSCIENCE®), PerCP-Cy5.5-IgD (11-26c.2a, BIOLEGEND®), Pacific Blue-CD3 (17A2, BIOLEGEND®), APC-B220 (RA3-6B2, EBIOSCIENCE®), APC-H7-CD19 (ID3, BD Biosciences).
- Bone marrow immature B cells (B220 int IgM + ), mature B cells (B220 hi IgM + ), pro B cells (CD19 + ckit + CD43 + ), pre B cells (CD19 + ckit ⁇ CD43 ⁇ ), immature Ig ⁇ + B cells (B220 int IgM + Ig ⁇ + Ig ⁇ ⁇ ), immature Ig ⁇ + B cells (B220 int IgM + Ig ⁇ ⁇ Ig ⁇ + ), mature Ig ⁇ + B cells (B220 hi IgM + Ig ⁇ + Ig ⁇ ⁇ ), mature Ig ⁇ + B cells (B220 hi IgM + Ig ⁇ ⁇ Ig ⁇ + ).
- B cells (CD19 + ), mature B cells (CD19 + IgD hi IgM int ), transitional/immature B cells (CD19 + IgD int IgM hi ).
- Bone marrow and spleen Ig ⁇ + B cells (CD19 + Ig ⁇ + Ig ⁇ ⁇ ), Ig ⁇ + B cells (CD19 + Ig ⁇ ⁇ Ig ⁇ + ).
- results for the splenic compartment are shown in FIGS. 3, 4A and 5-7 .
- Results for the bone marrow compartment are shown in FIGS. 4B and 8-11B .
- V H 1-69 gene segment Expression of the human V H 1-69 gene segment was determined for mice heterozygous and homozygous for a human V H 1-69 gene segment, all human D H and J H gene segments operably linked to mouse heavy chain constant regions by a quantitative PCR assay using TAQMAN® probes.
- Total RNA was purified using the RNEASYTM Mini kit (Qiagen) and genomic RNA was removed using an RNase-free DNase on-column treatment (Qiagen).
- About 200 ng mRNA was reverse-transcribed into cDNA using the First Stand cDNA Synthesis kit (Invitrogen), followed by amplification with the TAQMAN® Universal PCR Master Mix (Applied Biosystems) using the ABI 7900 Sequence Detection System (Applied Biosystems).
- Unique primer/probe combinations were employed to specifically determine expression of human V H 1-69-derived heavy chains (Table 5). Relative expression was normalized to the mouse ⁇ constant region (mC ⁇ ). The results are shown in FIG. 12 .
- the humoral immune response was determined for mice homozygous for human heavy and ⁇ light chain variable gene loci (H ⁇ ) and mice homozygous for a single human V H gene segment, all human D H and J H gene segments operably linked to mouse heavy chain constant regions (1hV H HO) by comparative immunization using a human cell surface receptor (Antigen A).
- mice Serum was collected from groups of mice prior to immunization with the above antigen.
- Antigen (2.35 ⁇ g each) was administered in an initial priming immunization mixed with 10 ⁇ g of CpG oligonucleotide (Invivogen) and 25 ⁇ g of Adju-phos (Brenntag) as adjuvants.
- the immunogen was administered via footpad (f.p.) in a volume of 25 ⁇ l per mouse.
- mice were boosted via f.p. with 2.3 ⁇ g of antigen along with 10 ⁇ g CpG and 25 ⁇ g Adju-Phos as adjuvants on days 3, 6, 11, 13, 17, and 20 for a total of six boosts.
- Mice were bled on days 15 and 22 after the fourth and sixth boosts, respectively, and antisera were assayed for antibody titers to Antigen A.
- Antibody titers were determined in sera of immunized mice using an ELISA assay.
- Ninety six-well microtiter plates (Thermo Scientific) were coated with Antigen A (1 ⁇ g/ml) in phosphate-buffered saline (PBS, Irvine Scientific) overnight at 4° C. The following day, plates were washed with phosphate-buffered saline containing 0.05% Tween 20 (PBS-T, Sigma-Aldrich) four times using a plate washer (Molecular Devices). Plates were then blocked with 250 ⁇ l of 1% bovine serum albumin (BSA, Sigma-Aldrich) in PBS and incubated for one hour at room temperature.
- BSA bovine serum albumin
- Serum titer was calculated as serum dilution within experimental titration range at the signal of antigen binding equivalent to two times above background.
- Antibody titer for the humoral immune response against a human cell surface receptor (Antigen A) is set forth in FIG. 19 .
- mice serum was collected from groups of mice prior to immunization with the above antigen (as described above).
- Mice (n 5) homozygous for a single human V H gene segment (V H 1-69), all human D H and J H gene segments operably linked to mouse heavy chain constant regions (1hV H HO) were immunized intra-nasally (i.n.) with FLUMIST® (live attenuated influenza vaccine) at 1 ⁇ 3 the normal dose/mouse.
- FLUMIST® live attenuated influenza vaccine
- One normal dose of FLUMIST® contains 10 6.5-7.5 FFU (fluorescent focus units) of live attenuated influenza vaccine. Therefore, each mouse was primed with 70 ⁇ l FLUMIST® on day 1 followed by i.n.
- mice were bled on days 15 and 22 after 4th and 6th boosts respectively and antiserum assayed for antibody titers to FLUMIST® (as described above).
- mice in immunizations with FLUVIRIN®, pre-immune serum was collected from mice prior to initiation of immunization.
- Serum titer was calculated as serum dilution within experimental titration range at the signal of antigen binding equivalent to two times above background.
- Antibody titer for the humoral immune response against FLUMIST® and FLUVIRIN® is set forth in FIG. 20 .
- mice having immunoglobulin heavy chain loci restricted to a single V H gene segment are capable of mounting a robust immune response to antigen in a manner comparable to mice having immunoglobulin heavy chain loci containing a plurality of human V H gene segments (e.g., 80 V H ).
- Splenocytes harvested from mice homozygous for a single human V H gene segment at the endogenous heavy chain locus and homozygous for a replacement of the endogenous ⁇ light chain variable loci with human ⁇ light chain variable loci immunized with a human cell surface receptor (Antigen A) were analyzed for heavy and light chain gene segment usage by reverse-transcriptase polymerase chain reaction (RT-PCR) on mRNA from splenic B cells.
- RT-PCR reverse-transcriptase polymerase chain reaction
- spleens were harvested and homogenized in 1 ⁇ PBS (Gibco) using glass slides. Cells were pelleted in a centrifuge (500 ⁇ g for 5 minutes), and red blood cells were lysed in ACK Lysis buffer (Gibco) for 3 minutes. Cells were washed with 1 ⁇ PBS and filtered using a 0.7 ⁇ m cell strainer. B-cells were isolated from spleen cells using MACS magnetic positive selection for CD19 (Miltenyi Biotec). Total RNA was isolated from pelleted B-cells using the RNeasy Plus Kit (Qiagen). PolyA + mRNA was isolated from total RNA using the Oligotex® Direct mRNA mini kit (Qiagen).
- Double-stranded cDNA was prepared from splenic B cell mRNA by 5′ RACE using the SMARTerTM Pico cDNA Synthesis Kit (Clontech) with substitution of the supplied reverse transcriptase and dNTPs with Superscript® II and dNTPs (Invitrogen).
- V H and V ⁇ antibody repertoires were amplified from the cDNA using primers specific for IgM, IgG, or Ig ⁇ constant regions and the SMARTerTM 5′ RACE primer (Table 6). PCR products were purified using a QIAquick® PCR Purification Kit (Qiagen).
- a second round of PCR was done using the same 5′ RACE primer and a nested 3′ primer specific for the IgM, IgG, or Ig ⁇ constant regions (Table 7).
- Second round PCR products were purified using a SizeSelectTM E-Gel® system (Invitrogen).
- a third PCR was performed with primers that added 454 adapters and barcodes.
- Third round PCR products were purified using Agencourt® AMPure® XP Beads (Beckman Coulter). Purified PCR products were quantified by SYBR® qPCR using a KAPA Library Quantification Kit (KAPA Biosystems).
- emulsion PCR emulsion PCR
- 454 GS Junior Titanium Series Lib-A emPCR Kit Roche Diagnostics
- bidirectional sequencing using Roche 454 GS Junior instrument according to manufacturer's specifications.
- the 454 sequences were sorted based on the sample barcode perfect match and trimmed for quality. Sequences were annotated based on alignment of rearranged immunoglobulin sequences to human germline V(D)J segment database using local installation of Igblast (NCBI, v2.2.25+). A sequence was marked as ambiguous and removed from analysis when multiple best hits with identical score were detected. A set of perl scripts was developed to analyze results and store data in mysql database. CDR3 region was defined between conserved C codon and FGXG motif for light and WGXG motif for heavy chains. CDR3 length was determined using only productive antibodies.
- Table 8 sets forth the percentage of observed human D H and J H gene segments used among IgM-primed (15,650 sequences) and IgG-primed (18,967 sequences) V H 1-69 derived heavy chain variable region sequences.
- Human D H 4-4/D H 4-11 and human D H 5-5/D H 5-18 gene segments are presented in Table 8 together due to identical sequence identity between the respective pairs of D H gene segments.
- Table 9 sets forth the percentage of human V ⁇ and J ⁇ gene segments observed among light chains (26,804 sequences) cognate with V H 1-69 derived heavy chain variable regions. Percentages in Tables 8 and 9 represent rounded values and in some cases may not equal 100% when added together.
- Amino acid length of the CDR3 region of IgM-primed V H 1-69-derived heavy chains is shown in FIG. 21 .
- Amino acid length of the CDR3 region of IgG-primed V H 1-69-derived heavy chains is shown in FIG. 22 .
- mice according to the invention generate antigen-specific antibodies containing V H 1-69-derived heavy chains, which demonstrate a variety of rearrangements of a human V H 1-69 gene segment with a variety of human D H segments and human J H segments. Further, the antigen-specific antibodies contain cognate human light chains containing human V ⁇ domains resulting from a variety of rearrangements of human V ⁇ and J ⁇ gene segments.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/653,456 US10246509B2 (en) | 2011-10-17 | 2012-10-17 | Restricted immunoglobulin heavy chain mice |
US13/944,286 US9932398B2 (en) | 2011-10-17 | 2013-07-17 | Restricted immunoglobulin heavy chain mice |
US16/265,825 US11261248B2 (en) | 2011-10-17 | 2019-02-01 | Restricted immunoglobulin heavy chain mice |
US16/851,902 US20200277371A1 (en) | 2011-10-17 | 2020-04-17 | Restricted Immunoglobulin Heavy Chain Mice |
US17/579,185 US20220177572A1 (en) | 2011-10-17 | 2022-01-19 | Restricted immunoglobulin heavy chain mice |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161547974P | 2011-10-17 | 2011-10-17 | |
US201261597969P | 2012-02-13 | 2012-02-13 | |
US201261658459P | 2012-06-12 | 2012-06-12 | |
US13/653,456 US10246509B2 (en) | 2011-10-17 | 2012-10-17 | Restricted immunoglobulin heavy chain mice |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/944,286 Division US9932398B2 (en) | 2011-10-17 | 2013-07-17 | Restricted immunoglobulin heavy chain mice |
US16/265,825 Division US11261248B2 (en) | 2011-10-17 | 2019-02-01 | Restricted immunoglobulin heavy chain mice |
Publications (2)
Publication Number | Publication Date |
---|---|
US20130096287A1 US20130096287A1 (en) | 2013-04-18 |
US10246509B2 true US10246509B2 (en) | 2019-04-02 |
Family
ID=47144131
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/653,456 Active US10246509B2 (en) | 2011-10-17 | 2012-10-17 | Restricted immunoglobulin heavy chain mice |
US13/944,286 Active 2034-05-02 US9932398B2 (en) | 2011-10-17 | 2013-07-17 | Restricted immunoglobulin heavy chain mice |
US16/265,825 Active 2033-05-31 US11261248B2 (en) | 2011-10-17 | 2019-02-01 | Restricted immunoglobulin heavy chain mice |
US16/851,902 Abandoned US20200277371A1 (en) | 2011-10-17 | 2020-04-17 | Restricted Immunoglobulin Heavy Chain Mice |
US17/579,185 Pending US20220177572A1 (en) | 2011-10-17 | 2022-01-19 | Restricted immunoglobulin heavy chain mice |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/944,286 Active 2034-05-02 US9932398B2 (en) | 2011-10-17 | 2013-07-17 | Restricted immunoglobulin heavy chain mice |
US16/265,825 Active 2033-05-31 US11261248B2 (en) | 2011-10-17 | 2019-02-01 | Restricted immunoglobulin heavy chain mice |
US16/851,902 Abandoned US20200277371A1 (en) | 2011-10-17 | 2020-04-17 | Restricted Immunoglobulin Heavy Chain Mice |
US17/579,185 Pending US20220177572A1 (en) | 2011-10-17 | 2022-01-19 | Restricted immunoglobulin heavy chain mice |
Country Status (26)
Country | Link |
---|---|
US (5) | US10246509B2 (ru) |
EP (3) | EP4074833A1 (ru) |
JP (6) | JP6271435B2 (ru) |
KR (6) | KR20240006704A (ru) |
CN (3) | CN108200885B (ru) |
AU (4) | AU2012326283C1 (ru) |
BR (1) | BR112014008775A8 (ru) |
CA (1) | CA2850534A1 (ru) |
CY (2) | CY1119335T1 (ru) |
DK (2) | DK3216871T3 (ru) |
ES (2) | ES2906462T3 (ru) |
HR (2) | HRP20220253T1 (ru) |
HU (2) | HUE057680T2 (ru) |
IL (5) | IL292030B2 (ru) |
IN (1) | IN2014CN03572A (ru) |
LT (2) | LT2627773T (ru) |
MX (1) | MX355062B (ru) |
MY (1) | MY172946A (ru) |
PL (2) | PL2627773T3 (ru) |
PT (2) | PT3216871T (ru) |
RS (2) | RS62942B1 (ru) |
RU (2) | RU2603090C2 (ru) |
SG (3) | SG11201401181YA (ru) |
SI (2) | SI2627773T1 (ru) |
WO (1) | WO2013059230A1 (ru) |
ZA (1) | ZA201402455B (ru) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200277371A1 (en) * | 2011-10-17 | 2020-09-03 | Regeneron Pharmaceuticals, Inc. | Restricted Immunoglobulin Heavy Chain Mice |
WO2022056276A1 (en) | 2020-09-11 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
WO2022132943A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
EP3028565B1 (en) | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
ES2728942T3 (es) | 2010-02-08 | 2019-10-29 | Regeneron Pharma | Cadena ligera común de ratón |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
EP2601298B1 (en) | 2010-08-02 | 2016-11-30 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
PL2738258T5 (pl) | 2011-02-25 | 2023-05-15 | Regeneron Pharmaceuticals, Inc. | Myszy adam6 |
SG10201914002RA (en) | 2011-08-05 | 2020-03-30 | Regeneron Pharma | Humanized universal light chain mice |
CA2846319A1 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
AU2012323987B2 (en) | 2011-12-20 | 2015-07-09 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
LT2858487T (lt) * | 2012-06-12 | 2019-12-27 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, kurie yra humanizuoti ir turi redukuotą imunoglobulino sunkiosios grandinės lokusą |
AU2014218915B2 (en) | 2013-02-20 | 2017-01-19 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
EP3096609B1 (en) * | 2014-01-24 | 2021-09-22 | Children's Medical Center Corporation | High-throughput mouse model for optimizing antibody affinities |
JP2017510273A (ja) | 2014-03-21 | 2017-04-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 異なる結合特性を示すvl抗原結合タンパク質 |
KR102601491B1 (ko) | 2014-03-21 | 2023-11-13 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
US20170121399A1 (en) | 2014-05-16 | 2017-05-04 | Ablynx N.V. | Improved immunoglobulin variable domains |
EP3248986B1 (en) | 2014-05-16 | 2022-01-26 | Ablynx NV | Immunoglobulin variable domains |
CN107438622A (zh) | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
IL302725A (en) | 2016-01-13 | 2023-07-01 | Regeneron Pharma | Rodents with an engineered DIVERSITY region of the heavy chain |
WO2017143062A1 (en) | 2016-02-16 | 2017-08-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a mutant kynureninase gene |
KR102356542B1 (ko) | 2016-05-20 | 2022-01-28 | 리제너론 파마슈티칼스 인코포레이티드 | 다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법 |
IL263160B2 (en) | 2016-06-03 | 2024-01-01 | Regeneron Pharma | Non-human animals expressing exogenous terminal deoxynucleotidyl transferase |
CN109996441B (zh) | 2016-11-04 | 2022-02-08 | 瑞泽恩制药公司 | 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物 |
CN108265035A (zh) * | 2016-12-30 | 2018-07-10 | 深圳先进技术研究院 | 一种进化噬菌体宿主特异性的方法 |
US11051498B2 (en) | 2017-12-05 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Mouse having an engineered immunoglobulin lambda light chain |
BR112020019026A2 (pt) | 2018-03-24 | 2020-12-29 | Regeneron Pharmaceuticals, Inc. | Animal não humano geneticamente modificado, métodos para produzir o animal não humano geneticamente modificado, para geração de uma proteína de ligação a antígeno, para obtenção de um ácido nucleico, e, para obtenção de uma célula que expressa um domínio variável de cadeia pesada de imunoglobulina humana e/ou um domínio variável de cadeia leve de imunoglobulina humana, método in vitro de produção de um domínio variável de imunoglobulina humana, ácido nucleico, célula hospedeira, célula isolada, e, domínio variável de cadeia pesada de imunoglobulina humana |
CN116420679A (zh) | 2018-03-26 | 2023-07-14 | 瑞泽恩制药公司 | 用于测试治疗剂的人源化啮齿动物 |
LT3629720T (lt) | 2018-06-14 | 2022-03-10 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, gebantys vykdyti imunoglobulino sunkiosios grandinės koduojančių sekų dh-dh pertvarkymą |
CA3136478A1 (en) | 2019-06-05 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
CN114901678A (zh) | 2019-12-02 | 2022-08-12 | 瑞泽恩制药公司 | 肽-mhc ii蛋白构建体及其用途 |
CA3165366A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
WO2023179620A1 (en) * | 2022-03-21 | 2023-09-28 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin and mhc loci |
Citations (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990004036A1 (en) | 1988-10-12 | 1990-04-19 | Medical Research Council | Production of antibodies from transgenic animals |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1998024893A2 (en) | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CN1203922A (zh) | 1997-03-21 | 1999-01-06 | 三共株式会社 | 人源化抗人fas抗体 |
US5939598A (en) | 1990-01-12 | 1999-08-17 | Abgenix, Inc. | Method of making transgenic mice lacking endogenous heavy chains |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO2000073323A2 (en) | 1999-05-27 | 2000-12-07 | Human Genome Sciences, Inc. | Adam polynucleotides and polypeptides |
US6162963A (en) | 1990-01-12 | 2000-12-19 | Abgenix, Inc. | Generation of Xenogenetic antibodies |
WO2002012437A2 (en) | 2000-08-03 | 2002-02-14 | Schooten Wim Van | Production of humanized antibodies in transgenic animals |
WO2002046237A2 (en) | 2000-12-06 | 2002-06-13 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US20020106629A1 (en) | 2000-10-31 | 2002-08-08 | Murphy Andrew J. | Methods of modifying eukaryotic cells |
US20020106628A1 (en) | 2000-10-31 | 2002-08-08 | Economides Aris N. | Methods of modifying eukaryotic cells |
WO2002085944A2 (en) | 2001-04-24 | 2002-10-31 | Erasmus Universiteit Rotterdam | Single chain camelid vhh antibodies, method for their production in a mammal and their uses |
US20030109021A1 (en) | 2001-04-26 | 2003-06-12 | Shujian Wu | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
US20030108925A1 (en) | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO2004049794A2 (en) | 2002-12-03 | 2004-06-17 | The Babraham Institute | Single chain antibodies produced in a transgenic mouse |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
WO2005019463A1 (en) | 2003-08-11 | 2005-03-03 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis with humanized immunoglobulin loci |
WO2005028510A2 (en) | 2003-09-25 | 2005-03-31 | Vsevolod Ivanovich Kiselev | Methods, kits, and compositions for the development and use of monoclonal antibodies specific to antigens of low immunogenicity |
WO2005038001A2 (en) | 2003-10-14 | 2005-04-28 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis by sperm-mediated gene transfer |
US20060015958A1 (en) | 2001-05-11 | 2006-01-19 | Kirin Beer Kabushiki Kaisha | Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission |
US20060015957A1 (en) | 1991-08-28 | 2006-01-19 | Genpharm International, Inc. | Transgenic non-human animals for producing chimeric antibodies |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
WO2006117699A2 (en) | 2005-04-29 | 2006-11-09 | Innate Pharma | Transgenic animals and methods of making recombinant antibodies |
US7183076B2 (en) | 1997-05-02 | 2007-02-27 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
WO2007096779A2 (en) | 2006-01-25 | 2007-08-30 | Erasmus University Medical Center Rotterdam | Generation of heavy-chain only antibodies in transgenic animals |
WO2007117410A2 (en) | 2006-03-31 | 2007-10-18 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
WO2008151081A1 (en) | 2007-06-01 | 2008-12-11 | Omt, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
WO2009076464A2 (en) | 2007-12-10 | 2009-06-18 | Aliva Biopharmaceuticals, Inc. | Methods for sequential replacement of targeted region by homologous recombination |
WO2009097006A2 (en) | 2007-08-10 | 2009-08-06 | Medarex, Inc. | Hco32 and hco27 and related examples |
US7582298B2 (en) | 2006-06-02 | 2009-09-01 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
US7585668B2 (en) | 2003-07-15 | 2009-09-08 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
US20090258392A1 (en) | 2008-04-14 | 2009-10-15 | Michael Gallo | Sequence diversity generation in immunoglobulins |
WO2009143472A2 (en) | 2008-05-23 | 2009-11-26 | Aliva Biopharmaceuticals, Inc. | Method of generating single vl domain antibodies in transgenic animals |
WO2010039900A2 (en) | 2008-09-30 | 2010-04-08 | Aliva Biopharmaceuticals, Inc. | Non-human mammals for the production of chimeric antibodies |
US20100146647A1 (en) | 2008-06-27 | 2010-06-10 | Merus B. V. | Antibody producing non-human mammals |
WO2011004192A1 (en) | 2009-07-08 | 2011-01-13 | Genome Research Limited | Animal models and therapeutic molecules |
US20110111406A1 (en) | 2008-04-11 | 2011-05-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
WO2011072204A1 (en) | 2009-12-10 | 2011-06-16 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
US20110195454A1 (en) | 2010-02-08 | 2011-08-11 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
WO2011158009A1 (en) | 2010-06-17 | 2011-12-22 | Kymab Limited | Animal models and therapeutic molecules |
US20110314563A1 (en) | 2008-12-18 | 2011-12-22 | Kingdon Craig R | Antibody production |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US20120096572A1 (en) | 2010-08-02 | 2012-04-19 | Regeneron Pharmaceuticals, Inc. | Mice That Make VL Binding Proteins |
WO2012063048A1 (en) | 2010-11-08 | 2012-05-18 | Kymab Limited | Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
US20120167237A1 (en) | 2009-07-08 | 2012-06-28 | Kymab Limited | Animal models and therapeutic molecules |
WO2012141798A1 (en) | 2011-02-25 | 2012-10-18 | Regeneron Pharmaceuticals, Inc. | Adam6 mice |
WO2013022782A1 (en) | 2011-08-05 | 2013-02-14 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
WO2013041846A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
WO2013041845A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Animals, repertoires & methods |
WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
US20130096287A1 (en) | 2011-10-17 | 2013-04-18 | Regeneron Pharmaceuticals, Inc. | Restricted Immunoglobulin Heavy Chain Mice |
WO2013061078A1 (en) | 2011-10-28 | 2013-05-02 | Kymab Limited | Transgenic non-human assay vertebrates, assays & kits |
WO2013061098A2 (en) | 2011-12-02 | 2013-05-02 | Kymab Limited | Functional isotype switching of chimaeric antibody chains & chimaeric animals expressing different igh isotypes |
WO2013079953A1 (en) | 2011-12-02 | 2013-06-06 | Kymab Limited | Fertile transgenic animals useful for producing antibodies bearing human variable regions |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US20130198880A1 (en) | 2010-02-08 | 2013-08-01 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
WO2013138680A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US20130243773A1 (en) | 2002-07-18 | 2013-09-19 | Merus B.V. | Recombinant production of mixtures of antibodies |
WO2013144567A1 (en) | 2012-03-28 | 2013-10-03 | Kymab Limited | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
WO2013171505A2 (en) | 2012-05-17 | 2013-11-21 | Kymab Limited | In vivo guided selection & antibodies |
US20130323235A1 (en) | 2009-03-24 | 2013-12-05 | Erasmus University Medical Center | Soluble heavy-chain only antibodies |
US20130333057A1 (en) | 2012-06-12 | 2013-12-12 | Regeneron Pharmaceuticals, Inc. | Humanized Non-Human Animals with Restricted Immunoglobulin Heavy Chain Loci |
WO2014130690A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
WO2014160202A1 (en) | 2013-03-13 | 2014-10-02 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
CA2219361C (en) * | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
FI105105B (fi) * | 1998-02-27 | 2000-06-15 | Finnish Immunotechnology Ltd O | Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan |
CN101498731A (zh) * | 2000-05-18 | 2009-08-05 | 日本烟草产业株式会社 | 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途 |
US20020028488A1 (en) * | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
AU2004286198C1 (en) | 2003-08-18 | 2011-02-24 | Medimmune, Llc | Humanization of antibodies |
CN101076542A (zh) * | 2004-09-13 | 2007-11-21 | 伊沃詹尼克斯有限公司 | 特异性针对肝细胞癌和其他癌的抗体及其用途 |
WO2009138519A1 (en) * | 2008-05-16 | 2009-11-19 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
EP2201040A1 (en) * | 2007-09-24 | 2010-06-30 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses thereof |
WO2010151792A1 (en) * | 2009-06-26 | 2010-12-29 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
AU2012323987B2 (en) * | 2011-12-20 | 2015-07-09 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
-
2012
- 2012-10-17 CN CN201710933685.9A patent/CN108200885B/zh active Active
- 2012-10-17 EP EP21208060.0A patent/EP4074833A1/en active Pending
- 2012-10-17 IL IL292030A patent/IL292030B2/en unknown
- 2012-10-17 US US13/653,456 patent/US10246509B2/en active Active
- 2012-10-17 CA CA2850534A patent/CA2850534A1/en active Pending
- 2012-10-17 IN IN3572CHN2014 patent/IN2014CN03572A/en unknown
- 2012-10-17 KR KR1020237045077A patent/KR20240006704A/ko not_active Application Discontinuation
- 2012-10-17 RS RS20220181A patent/RS62942B1/sr unknown
- 2012-10-17 SG SG11201401181YA patent/SG11201401181YA/en unknown
- 2012-10-17 SI SI201231055T patent/SI2627773T1/sl unknown
- 2012-10-17 KR KR1020167021090A patent/KR20160098514A/ko active Search and Examination
- 2012-10-17 KR KR1020147013282A patent/KR20140082824A/ko active Search and Examination
- 2012-10-17 MY MYPI2014000810A patent/MY172946A/en unknown
- 2012-10-17 DK DK17163115.3T patent/DK3216871T3/da active
- 2012-10-17 RS RS20170893A patent/RS56458B1/sr unknown
- 2012-10-17 ES ES17163115T patent/ES2906462T3/es active Active
- 2012-10-17 ES ES12783456.2T patent/ES2640139T3/es active Active
- 2012-10-17 SI SI201231981T patent/SI3216871T1/sl unknown
- 2012-10-17 HU HUE17163115A patent/HUE057680T2/hu unknown
- 2012-10-17 PL PL12783456T patent/PL2627773T3/pl unknown
- 2012-10-17 RU RU2014118869/10A patent/RU2603090C2/ru active
- 2012-10-17 EP EP12783456.2A patent/EP2627773B1/en active Active
- 2012-10-17 KR KR1020197021940A patent/KR102148683B1/ko active IP Right Grant
- 2012-10-17 MX MX2014004354A patent/MX355062B/es active IP Right Grant
- 2012-10-17 RU RU2016139418A patent/RU2743589C2/ru active
- 2012-10-17 HR HRP20220253TT patent/HRP20220253T1/hr unknown
- 2012-10-17 EP EP17163115.3A patent/EP3216871B1/en active Active
- 2012-10-17 PT PT171631153T patent/PT3216871T/pt unknown
- 2012-10-17 CN CN201280062449.XA patent/CN104024418B/zh active Active
- 2012-10-17 HU HUE12783456A patent/HUE034321T2/en unknown
- 2012-10-17 KR KR1020217028212A patent/KR20210113419A/ko not_active IP Right Cessation
- 2012-10-17 LT LTEP12783456.2T patent/LT2627773T/lt unknown
- 2012-10-17 PT PT127834562T patent/PT2627773T/pt unknown
- 2012-10-17 DK DK12783456.2T patent/DK2627773T3/en active
- 2012-10-17 CN CN201710933842.6A patent/CN108207807B/zh active Active
- 2012-10-17 SG SG10202010120XA patent/SG10202010120XA/en unknown
- 2012-10-17 SG SG10201602904VA patent/SG10201602904VA/en unknown
- 2012-10-17 WO PCT/US2012/060487 patent/WO2013059230A1/en active Application Filing
- 2012-10-17 JP JP2014535991A patent/JP6271435B2/ja active Active
- 2012-10-17 BR BR112014008775A patent/BR112014008775A8/pt not_active Application Discontinuation
- 2012-10-17 LT LTEP17163115.3T patent/LT3216871T/lt unknown
- 2012-10-17 KR KR1020207012383A patent/KR20200047786A/ko not_active IP Right Cessation
- 2012-10-17 AU AU2012326283A patent/AU2012326283C1/en active Active
- 2012-10-17 PL PL17163115T patent/PL3216871T3/pl unknown
-
2013
- 2013-07-17 US US13/944,286 patent/US9932398B2/en active Active
-
2014
- 2014-03-31 IL IL231819A patent/IL231819A0/en active IP Right Grant
- 2014-04-01 ZA ZA2014/02455A patent/ZA201402455B/en unknown
-
2015
- 2015-11-12 JP JP2015222017A patent/JP2016039820A/ja active Pending
-
2016
- 2016-06-17 AU AU2016204127A patent/AU2016204127C1/en active Active
-
2017
- 2017-09-11 HR HRP20171357TT patent/HRP20171357T1/hr unknown
- 2017-09-12 CY CY20171100960T patent/CY1119335T1/el unknown
- 2017-09-27 JP JP2017186356A patent/JP2017221223A/ja active Pending
-
2018
- 2018-05-30 AU AU2018203811A patent/AU2018203811B2/en active Active
- 2018-08-20 IL IL261242A patent/IL261242A/en active IP Right Grant
- 2018-12-27 JP JP2018244321A patent/JP6770568B2/ja active Active
-
2019
- 2019-02-01 US US16/265,825 patent/US11261248B2/en active Active
- 2019-04-11 IL IL265967A patent/IL265967B/en active IP Right Grant
-
2020
- 2020-04-17 US US16/851,902 patent/US20200277371A1/en not_active Abandoned
- 2020-09-25 JP JP2020161346A patent/JP7022803B2/ja active Active
- 2020-12-18 AU AU2020289846A patent/AU2020289846A1/en not_active Abandoned
-
2021
- 2021-04-08 IL IL282200A patent/IL282200B/en unknown
- 2021-12-29 JP JP2021215393A patent/JP2022048158A/ja not_active Withdrawn
-
2022
- 2022-01-19 US US17/579,185 patent/US20220177572A1/en active Pending
- 2022-02-07 CY CY20221100102T patent/CY1124972T1/el unknown
Patent Citations (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545807A (en) | 1988-10-12 | 1996-08-13 | The Babraham Institute | Production of antibodies from transgenic animals |
WO1990004036A1 (en) | 1988-10-12 | 1990-04-19 | Medical Research Council | Production of antibodies from transgenic animals |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6162963A (en) | 1990-01-12 | 2000-12-19 | Abgenix, Inc. | Generation of Xenogenetic antibodies |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5939598A (en) | 1990-01-12 | 1999-08-17 | Abgenix, Inc. | Method of making transgenic mice lacking endogenous heavy chains |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7501552B2 (en) | 1991-08-28 | 2009-03-10 | Medarex, Inc. | Transgenic non-human animals for producing chimeric antibodies |
US20060015957A1 (en) | 1991-08-28 | 2006-01-19 | Genpharm International, Inc. | Transgenic non-human animals for producing chimeric antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US8158419B2 (en) | 1994-03-09 | 2012-04-17 | Medarex, Inc. | Transgenic non-human animals for producing chimeric antibodies |
US20150250152A1 (en) | 1996-12-03 | 2015-09-10 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
KR20050042792A (ko) | 1996-12-03 | 2005-05-10 | 아브게닉스, 인크. | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체 |
WO1998024893A2 (en) | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM |
CN1203922A (zh) | 1997-03-21 | 1999-01-06 | 三共株式会社 | 人源化抗人fas抗体 |
US7183076B2 (en) | 1997-05-02 | 2007-02-27 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
WO2000073323A2 (en) | 1999-05-27 | 2000-12-07 | Human Genome Sciences, Inc. | Adam polynucleotides and polypeptides |
WO2002012437A2 (en) | 2000-08-03 | 2002-02-14 | Schooten Wim Van | Production of humanized antibodies in transgenic animals |
US8502018B2 (en) | 2000-10-31 | 2013-08-06 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20020106628A1 (en) | 2000-10-31 | 2002-08-08 | Economides Aris N. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20040018626A1 (en) | 2000-10-31 | 2004-01-29 | Murphy Andrew J. | Methods of modifying eukaryotic cells |
US20020106629A1 (en) | 2000-10-31 | 2002-08-08 | Murphy Andrew J. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
WO2002046237A2 (en) | 2000-12-06 | 2002-06-13 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2002066630A1 (en) | 2001-02-16 | 2002-08-29 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
WO2002085944A2 (en) | 2001-04-24 | 2002-10-31 | Erasmus Universiteit Rotterdam | Single chain camelid vhh antibodies, method for their production in a mammal and their uses |
US20030109021A1 (en) | 2001-04-26 | 2003-06-12 | Shujian Wu | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
US20060015958A1 (en) | 2001-05-11 | 2006-01-19 | Kirin Beer Kabushiki Kaisha | Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission |
US20030108925A1 (en) | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
US20130243773A1 (en) | 2002-07-18 | 2013-09-19 | Merus B.V. | Recombinant production of mixtures of antibodies |
WO2004049794A2 (en) | 2002-12-03 | 2004-06-17 | The Babraham Institute | Single chain antibodies produced in a transgenic mouse |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US7585668B2 (en) | 2003-07-15 | 2009-09-08 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
WO2005019463A1 (en) | 2003-08-11 | 2005-03-03 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis with humanized immunoglobulin loci |
US20080267982A1 (en) | 2003-09-25 | 2008-10-30 | Vsevolod Ivanovich Kiselev | Methods Kits and Compositions for the Developement and Use of Monoclonal Antibodies Specific to Anbtigens of Low Immunogenicity |
WO2005028510A2 (en) | 2003-09-25 | 2005-03-31 | Vsevolod Ivanovich Kiselev | Methods, kits, and compositions for the development and use of monoclonal antibodies specific to antigens of low immunogenicity |
WO2005038001A2 (en) | 2003-10-14 | 2005-04-28 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis by sperm-mediated gene transfer |
WO2006117699A2 (en) | 2005-04-29 | 2006-11-09 | Innate Pharma | Transgenic animals and methods of making recombinant antibodies |
WO2007096779A2 (en) | 2006-01-25 | 2007-08-30 | Erasmus University Medical Center Rotterdam | Generation of heavy-chain only antibodies in transgenic animals |
US7910798B2 (en) | 2006-03-31 | 2011-03-22 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
US20120272344A1 (en) | 2006-03-31 | 2012-10-25 | Tanamachi Dawn M | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
WO2007117410A2 (en) | 2006-03-31 | 2007-10-18 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
EP2003960B1 (en) | 2006-03-31 | 2015-06-10 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
US7582298B2 (en) | 2006-06-02 | 2009-09-01 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
WO2008151081A1 (en) | 2007-06-01 | 2008-12-11 | Omt, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
WO2009097006A2 (en) | 2007-08-10 | 2009-08-06 | Medarex, Inc. | Hco32 and hco27 and related examples |
US20120047585A1 (en) | 2007-08-10 | 2012-02-23 | Medarex, Inc. | Hco32 and hco27 and related examples |
WO2009076464A2 (en) | 2007-12-10 | 2009-06-18 | Aliva Biopharmaceuticals, Inc. | Methods for sequential replacement of targeted region by homologous recombination |
US20110111406A1 (en) | 2008-04-11 | 2011-05-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US20090258392A1 (en) | 2008-04-14 | 2009-10-15 | Michael Gallo | Sequence diversity generation in immunoglobulins |
WO2009143472A2 (en) | 2008-05-23 | 2009-11-26 | Aliva Biopharmaceuticals, Inc. | Method of generating single vl domain antibodies in transgenic animals |
US20100146647A1 (en) | 2008-06-27 | 2010-06-10 | Merus B. V. | Antibody producing non-human mammals |
US20110236378A1 (en) | 2008-09-30 | 2011-09-29 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
WO2010039900A2 (en) | 2008-09-30 | 2010-04-08 | Aliva Biopharmaceuticals, Inc. | Non-human mammals for the production of chimeric antibodies |
US20110314563A1 (en) | 2008-12-18 | 2011-12-22 | Kingdon Craig R | Antibody production |
US20130323235A1 (en) | 2009-03-24 | 2013-12-05 | Erasmus University Medical Center | Soluble heavy-chain only antibodies |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US20120167237A1 (en) | 2009-07-08 | 2012-06-28 | Kymab Limited | Animal models and therapeutic molecules |
WO2011004192A1 (en) | 2009-07-08 | 2011-01-13 | Genome Research Limited | Animal models and therapeutic molecules |
US8754287B2 (en) | 2009-12-10 | 2014-06-17 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
WO2011072204A1 (en) | 2009-12-10 | 2011-06-16 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
US20110195454A1 (en) | 2010-02-08 | 2011-08-11 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US20130198880A1 (en) | 2010-02-08 | 2013-08-01 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
WO2011158009A1 (en) | 2010-06-17 | 2011-12-22 | Kymab Limited | Animal models and therapeutic molecules |
US20120096572A1 (en) | 2010-08-02 | 2012-04-19 | Regeneron Pharmaceuticals, Inc. | Mice That Make VL Binding Proteins |
WO2012063048A1 (en) | 2010-11-08 | 2012-05-18 | Kymab Limited | Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
US8697940B2 (en) | 2011-02-25 | 2014-04-15 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US20150201589A1 (en) | 2011-02-25 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Adam6 mice |
US8642835B2 (en) | 2011-02-25 | 2014-02-04 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US20150210776A1 (en) | 2011-02-25 | 2015-07-30 | Regeneron Pharmaceuticals, Inc. | Adam6 mice |
WO2012141798A1 (en) | 2011-02-25 | 2012-10-18 | Regeneron Pharmaceuticals, Inc. | Adam6 mice |
WO2012148873A2 (en) | 2011-04-25 | 2012-11-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies having a common light chain |
WO2013022782A1 (en) | 2011-08-05 | 2013-02-14 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
US20130198879A1 (en) | 2011-08-05 | 2013-08-01 | Regeneron Pharmaceuticals, Inc. | Humanized Universal Light Chain Mice |
WO2013041846A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
WO2013041845A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Animals, repertoires & methods |
WO2013041844A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
US20130323791A1 (en) | 2011-10-17 | 2013-12-05 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
US20130096287A1 (en) | 2011-10-17 | 2013-04-18 | Regeneron Pharmaceuticals, Inc. | Restricted Immunoglobulin Heavy Chain Mice |
WO2013059230A1 (en) | 2011-10-17 | 2013-04-25 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
WO2013061078A1 (en) | 2011-10-28 | 2013-05-02 | Kymab Limited | Transgenic non-human assay vertebrates, assays & kits |
WO2013079953A1 (en) | 2011-12-02 | 2013-06-06 | Kymab Limited | Fertile transgenic animals useful for producing antibodies bearing human variable regions |
WO2013061098A2 (en) | 2011-12-02 | 2013-05-02 | Kymab Limited | Functional isotype switching of chimaeric antibody chains & chimaeric animals expressing different igh isotypes |
US20130243759A1 (en) | 2011-12-21 | 2013-09-19 | Kymab Ltd. | Transgenic Animals |
WO2013138680A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US20130263292A1 (en) | 2012-03-28 | 2013-10-03 | Kymab Limited | Animal models and therapeutic molecules |
WO2013144566A2 (en) | 2012-03-28 | 2013-10-03 | Kymab Limited | Animal models and therapeutic molecules |
WO2013144567A1 (en) | 2012-03-28 | 2013-10-03 | Kymab Limited | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
WO2013171505A2 (en) | 2012-05-17 | 2013-11-21 | Kymab Limited | In vivo guided selection & antibodies |
WO2013187953A1 (en) | 2012-06-12 | 2013-12-19 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
US20130333057A1 (en) | 2012-06-12 | 2013-12-12 | Regeneron Pharmaceuticals, Inc. | Humanized Non-Human Animals with Restricted Immunoglobulin Heavy Chain Loci |
US20150020224A1 (en) | 2013-02-20 | 2015-01-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
US20140245468A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
WO2014130690A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
US20160100561A1 (en) | 2013-02-20 | 2016-04-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
WO2014160202A1 (en) | 2013-03-13 | 2014-10-02 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
Non-Patent Citations (170)
Title |
---|
Adderson et al. 1991. Journal of Immunology 147(5):1667-1674. |
Adderson et al. 1993. Journal of Clinical Investigation 91:2734-2743. |
Adkins et al. (2004) "Neonatal Adaptive Immunity Comes of Age," Nature Reviews Immunol., 4:553-564. |
Amit and Itskovitz-Eldor (2009) "Embryonic Stem Cells: Isolation, Characterization and Culture," Adv. Biochem. Eng. Biotechnol., 114:173-184. |
Astellas Negotiates $295M License Extension to Regeneron's Veloclmmune mAb Platform, Genetic Engineering & Biotechnology News, Jul. 28, 2010, 2 pages. |
Austin et al. (2004) "The Knockout Mouse Project," Nature Genetics, 36(9):921-924. |
Bando et al. 2004. Immunology Letters 94:99-106. |
Baseggio et al. 2010. Haematologica 95(4):604-612. |
Bendig, Methods: A Companion to Methods in Enzymology, 1995; 8:83-93. * |
Berberian et al. 1991. Blood 78(1):175-179. |
Biao et al. (2013) "Human anitbody expression in transgenic rats: Comparison of chimeric IgH loci with human VH, D and JH but bearing different rat C-gene regions," Journal of Immunological Methods, 400:78-86. |
Brezinschek et al. 1995. Journal of Immunology 155:190-202. |
Briney, B. S., et al., "Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes," PLoS ONE, 2012, vol. 7, Issue 5, pp. 1-13. |
Brouwers et al. (2015) "Unexpected Phenotypes in Mouse Models Carrying the Human Growth Hormone Minigene to Enhance Transgene Expression," Journal of Steroids & Hormonal Science, 6(2):1-2. |
Brüggemann (2004) "Human Monoclonal Antibodies from Translocus Mice," Molecular Biology of B Cells, Eds. Honjo, T. and Neuberger, M.S., New York, NY: Academic Press, pp. 547-561. |
Brüggemann and Neuberger (1996) "Strategies for expressing human antibody repertoires in transgenic mice," Review Immunology Today, 192(17):391-397. |
Bruggemann et al. 1989. PNAS USA 86:6709-6713. |
Bruggemann. 2001. Archivum Immunologiae et Therapiae Experimentalis 49:203-208. |
Butler, (1998) "Immunoglobulin diversity, B-cell and antibody repertoire development in large farm animals," Rev. Sco. Tech. Off. Int. Epiz., 17(1):43-70. |
Canadian Office Action for Application No. 2,820,824, 3 pages, dated Aug. 5, 2014. |
Carbonari et al. 2005. Journal of Immunology 174:6352-6539. |
Chain, C. H., et al., "VHI-69 gene is perferentially used by neptitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen," Blood, 2001, vol. 97, No. 4, pp. 1023-1026. |
Chan et al. 2001. Blood 91(4):1023-1026. |
Charles et al. 2011. Journal of Immunol. Methods 363:210-220. |
Cheval et al. (2012) Of Mice and Men: Divergence of Gene Expression Patterns in Kidney, PLoS One, 7(10): e46876 (12 pages). |
Choi et al. (2011) "Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice," PNAS, 108(37):15219-15224. |
Choi, et al., "Characterization and comparative genomic analysis of intronless Adams with testicular gene expression," Genomics, 83(4):636-46 (2004) (Abstract Only). |
Chothia, C., et al., "Structural Repertoire of the Human VH Segments," J. Mol. Biol., 1992, vol. 227, pp. 799-817. |
Clark, et al., (2003) "A future for transgenic livestock," Nature Reviews Genetics, 4:825-833. |
Communication Relating to the Results of the Partial International Search for PCT/US2013/029624 (9 pages), dated May 17, 2013. |
Davidkova et al. 1997. Scand. Journal of Immunology 45:62-73. |
De Wildt et al. 1999. Journal of Molecular Biology 285:895-901. |
Defrancesco (1999) "Transgenic Mice that Produce Fully Humanized Antibodies-Abgenix Granted Patent," Bioprocess Online, 2 pages, Aug. 23, 1999. |
Defrancesco (1999) "Transgenic Mice that Produce Fully Humanized Antibodies—Abgenix Granted Patent," Bioprocess Online, 2 pages, Aug. 23, 1999. |
Dennis (2002) "Welfare issues of genetically modified animals," ILAR Journal, 43(2):100-109. |
Echelard, (2009) "Year of the ox," Nat. Biotechnol., 27(2):146-147. |
Edwards, et al., (2008) "The ADAM metalloproteinases," Molecular Aspects of Medicine, 29(5):258-89. |
EP1360287 Appeal Decision Mar. 10, 2016. |
Extended European Search Report with respect to EP 14754019.9 dated Aug. 28, 2015. |
Extended European Search Report with respect to EP 18158956.5 dated Jun. 8, 2018. |
Featherstone K. et al., The mouse immunoglobulin heavy chain V-D intergenic sequence contains insulators that may regulate ordered V(D)J recombination, The Journal of Biological Chemistry, 285(13):9327-38 (2010). |
Forconi, et al., (2010) "The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns of characteristic of unmutated CLL," Blood, vol. 115(1):71-77. |
Forconi, et al., (2010) "The normal IGHV1-69—derived B-cell repertoire contains stereotypic patterns of characteristic of unmutated CLL," Blood, vol. 115(1):71-77. |
Gallo et al. (2000) "The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans," Eur. J. Immunol., 30(2):534-540. |
Gay et al. (1993) "Receptor Editing: An Approach by Autoreactive B Cells to Escape Tolerance," J. Exp. Med., 177:999-1008. |
Genbank Accession AAA53514.1; GI:553403, 1 page, first referenced Jul. 30, 1993, updated Nov. 23, 1994. |
Giallourakis, et al., (2010) "Elements between the IgH variable (V) and diversity (D) clusters influence antisense transcription and lineage-specific V(D)J recombination," Proceedings of the National Academy of Sciences of the USA, 107(51):22207-12. |
Gorman et al. (1996) "The LGK 3' Enhancer Influences the Ratio of LGK Versus LGL B Lymphocytes," Immunity, 5(3):241-252. |
Han C. et al., Comprehensive analysis of reproductive ADAMs: relationship of ADAM4 and ADAM6; with an ADAM complex required for fertilization in mice, Biology of Reproduction, 80(5):1001-8 (2009). |
Harding and Lonberg (1995) "Class switching in human immunoglobulin transgenic Mice," Ann. N Y Acad. Sci., 764:536-546. |
Hendricks, et al., (2010) "Organization of the variable region of the immunoglobulin heavy-chain gene locus of the rat," Immunogenetics, 62(7):479-86. |
Hoiruchi and Blobel (2005) Studies from Adam Knockout Mice, in Hooper and Lendeckel, The Adam Family of proteases, Netherlands 2005, Springer (37 pages). |
Huang and Stollar. 1993. Journal of Immunology 151(10):5290-5300. |
International Search Report & Written Opinion with respect to PCT/US2012/026416, dated Jun. 25, 2012. |
International Search Report & Written Opinion with respect to PCT/US2014/17427 dated Aug. 1, 2014. |
International Search Report for PCT/US2012/060487 filed Oct. 17, 2012 dated Feb. 1, 2013, 7 pages. |
International Search Report for PCT/US2013/029624 (9 pages), dated Aug. 2, 2013. |
Johnson et al. 1997. Journal of Immunology 158:235-246. |
Kantor et al. 1997. Journal of Immunology 158:1175-1186. |
Kenny, et al. (2000) Positive and negative selection of antigen-specific B cells in transgenic mice expressing variant forms of the VH1 (T15) heavy chain, International Immunology, 12(6):873-885. |
Kim, et al., "Expression and relationship of male reproductive ADAMs in mouse," Biology of Reproduction, 74(4):744-50 (2006). |
Kong et al. (2009) "Transgene expression is associated with copy number and cytomegalovirus promoter methylation in transgenic pigs," PLoS One 4(8):1-10. |
Kunert et al. 2004. AIDS Research & Human Retroviruses 20(7):755-762. |
Kuroiwa et al. (2002) "Cloned transchromosomic calves producing human immunoglobulin," Nat. Biotechnol., 20(9):889-894. |
Kuroiwa et al. (2004) "Sequential targeting of the genes encoding immunoglobulin-μ and prion protein in cattle," Nature Genetics, 36:775-780. |
Lee et al. (2014) "Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery," Nature Biotechnology, 32(4):356. |
Lefranc, M. 2000. Current Protocols in Immunology. A.1P.1-A.1P.37. |
Lin et al. (1990) "Research of Immune Globulin in Mice," Guangzhou Medical Journal, 1:49-50, including English Translation. |
Liu et al. (2014) "Primary Genetic Investigation of a Hyperlipidemia Model: Molecular Characteristics and Variants of the Apolipoprotein E Gene in Mongolian Gerbil;" Biomed. Research International, (9 pages). |
Lonberg, N., "Human antibodies from transgenic animals," Nature Biotechnology, 2005, vol. 23, No. 9, pp. 1117-1125. |
Lovell-Badge (2007) "Many ways to pluripotency," Nature Biotechnology, 25:1114-1116. |
MacDonald et al. (2006) "Velocigene Technology Extended to Humanization of Several Megabases of complex Gene Loci," First International MUGEN Conference of Animal Models for Human Immunological Disease, Sep. 10-13, 2006-Athens, Greece, Abstract 21 and Poster, 2 pages original (pp. 3-11 are p. 2 of the original, enlarged). |
MacDonald et al. (2006) "Velocigene Technology Extended to Humanization of Several Megabases of complex Gene Loci," First International MUGEN Conference of Animal Models for Human Immunological Disease, Sep. 10-13, 2006—Athens, Greece, Abstract 21 and Poster, 2 pages original (pp. 3-11 are p. 2 of the original, enlarged). |
MacDonald et al. (2014) "Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes," Proceedings of the National Academy of Sciences, 111(14):5147-5152. |
Mageed et al. 2001. Clin. Exp. Immunol. 123:1-8. |
Mageed et al., "Rearrangement of the human heavy chain variable region gene V3-23 in transgenic mice generates antibodies reactive with a range of antigens on the basis of VHCDR3 and residues intrinsic to the heavy chain variable region," Clin Exp Immunol 123: 1-8, 2001. |
Mahmoud et al. 2011. Journal of Immunology 187:879-886. |
Mahmoudi et al. 1997. Lupus 6:578-589. |
Manis et al. (2002) "Mechanism and control of class-switch recombination," TRENDS in Immunology, 23(1):31-39. |
Marasca et al. 2001. American Journal of Pathology 159(1):253-261. |
Matsuda, F., et al., "The Complete Nucleotide Sequence of the Human Immunoglobulin Heavy Chain Variable Region Locus," J. Exp. Med., 1998, vol. 188, No. 11, pp. 2151-2162. |
McGoldrick et al. (2013) "Rodent models of amyotrophic lateral sclerosis," Biochimica et Biophysica Acta, 1832:1421-1436. |
Melton (2002) Chapter 8: Gene-Targeting Strategies, Methods in Molecular Biology, Transgenesis Techniques, 2nd Edition, Principles and Protocols, 180:19 pages. |
Mendez et al. (1997) "Functional Transplant of Megabase Human Immunoglobulin Loci Recapitulates Human Antibody Response in Mince," Nature 15:146-156. |
Miklos et al. 2000. Blood 95(12):3878-3884. |
Moran, Nuala, "Mouse platforms jostle for slice of humanized antibody market," Nature Biotechnology, vol. 31(4): 267-268, 2013. |
Mortari et al. 1993. Journal of Immunology 150(4):1348-1357. |
Muller et al. 1993. Scand. Journal of Immunology 38:327-334. |
Munoz et al., (2009) "Constraints to Progress in Embryonic Stem Cells from Domestic Species," Stem Cell Rev. and Rep, 5:6-9. |
Murphy (2014) Declaration Under 37 C.F.R. §1.132, 4 pages. |
Murphy and Silha (2000) "Unexpected and unexplained phenotypes in transgenic models," Growth Hormone & IGF Research, 10:233-235. |
Murphy et al. (2014) "Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice," Proceedings of the National Academy of Sciences, 111(14):5153-5158. |
Murphy PowerPoint (2009) BAC-based Modifications of the Mouse Genome: The Big and the Backward, Welcome Trust Advanced Course: Genetic Manipulation of ES Cells, 58 pages. |
Nadine Tuaillon, "Repertoire analysis in human immunoglobulin heavy chain minilocus transgenic, μMT/μMT mice," Molecular Immunology 37: 221-231, 2000. |
Nagle, Regeneron helps make Sanofi Veloclmmune to its "weak pipeline". <http://www.outsourcing-pharma.com> Published Dec. 3, 2007. |
Niemann, et al., (2005) "Transgenic farm animals: present and future," Rev. sci tech Off. Int. Epiz., 24 (1), 285-298. |
Non-Final Office Action dated Oct. 30, 2015 with Respect to U.S. Appl. No. 14/137,902. |
Office Action issued in U.S. Appl. No. 14/185,679, dated Dec. 1, 2017. |
Osborn et al. (2013) "High-Affinity IgG Antibodies Develop Naturally in Ig-Knockout Rats Carrying Germline Human IgH/Igκ/Igλ Loci Bearing the Rat CH Region," J. Immunol., 190:1481-1490. |
Pasqualini and Arap (2004) "Hybridoma-free generation of monoclonal antibodies," Proceedings of the National Academy of Sciences USA, 101(1):257-259. |
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under the heading "Fv Structure and Diversity in Three Dimensions". * |
PCT/US2013/029624 Invitation to Pay Additional Fees and Where Applicable, Protest Fee dated May 17, 2013, 9 pages. |
Perez et al. 2010. British Journal of Dermatology 162:611-618. |
Popov et al. (1999) "A Human Immunoglobulin lambda locus is Similarly Well Expressed in Mice and Humans," J. Exp. Med., 189(10):1611-1619. |
Pos et al. 2008. Journal of Thrombosis & Haemostasis 7:421-428. |
Poueymirou et al (2007) "F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses," Nat Biotechnol., 25, 91-99. |
Prelle, et al., (2002) "Pluripotent Stem Cells-Model of Embryonic Development, Tools for Gene Targeting, and Basis of Cell Therapy," Anat. Histol. Embryol., 31:169-186. |
Prelle, et al., (2002) "Pluripotent Stem Cells—Model of Embryonic Development, Tools for Gene Targeting, and Basis of Cell Therapy," Anat. Histol. Embryol., 31:169-186. |
Ramsden et al. (1994) "Conservation of sequence in recombination signal sequence spacers," Nucleic Acids Res., 22(10):1785-1796. |
Ray, (1991) "Ectopic expression of a c-kitW42 minigene in transgenic mice: recapitulation of W phenotypes and evidence for c-kit function in melanoblast progenitors," Genes Dev., 5(12A):2265-73. |
Regeneron v. Merus B.V. Opinion and Order Nov. 2, 2015. |
Rodriguez et al. 2000. Nature Genetics 25:139-140. |
Roebroek et al. (2003) "Chapter 10: Knockin Approaches," Methods in Molecular Biology, Transgenic Mouse Methods and Protocols, 209:16 pages. |
Romo-González, T. and Vargas-Madrazo, E., "Structural analysis of substitution patterns in alleles of human immunoglobulin VH genes," Molecular Immunology, 2005, vol. 42, pp. 1085-1097. |
Rudikoff et al. (1982) "Single amino acid substitution altering antigen-binding specificity," PNAS 79:1979-1983. |
Sasso et al, J Clin Invest, 1996, 97:2074-2080. * |
Sasso et al. 1990. Journal of Immunology 145(8):2751-2757. |
Sasso et al. 1993. Journal of Clinical Investigation 91:2358-2367. |
Sasso et al. 1996. Journal of Clinical Investigation 97(9):2074-2080. |
Schelonka et al. 2005. Journal of Immunology 175:6624-6632. |
Schulze et al. (2006) "Derivation, Maintenance, and Characterization of Rat Embryonic Stem Cells in Vitro," Methods in Molecular Biology, 329:45-58. |
Schwartz and Cantor (1984) "Separation of Yeast Chromosome-Sized DNAs by Pulsed Field Gradient Gel Electrophoresis," Cell, 37:67-75. |
Seals, et al., (2003) "The ADAMs family of metalloproteases: multidomain: proteins with multiple functions," Genes and Development, 17(1):7-30. |
Shmerling et al. (2005) "Strong and ubiquitous expression of transgenes targeted into the β-actin locus by Cre/lox cassette replacement," Genesis, 42(5):229-235. |
Sibilia et al. 1997. Journal of Immunology 159:712-719. |
Sigmund (2000) "Viewpoint: Are Studies in Genetically Altered Mice Out of Control?" Arterioscler. Thomb. Vasc. Biol., 20(6):1425-1429. |
Slick and Pasternak (2002) Molekulyarnaya biotekhnologiya. Printsipy i primeneniye, Moscow Mir., 45-47, including English translation. |
Sorrell and Kolb (2004) "Chapter XI: Targeted Modification of Mammalian Genomes," Focus on Genome Research, 6 pages. |
Souroujon et al. 1989. Journal of Immunology 143(2):706-711. |
Statement of Relatedness under MPEP 2001.06 dated Sep. 21, 2018 with Respect to U.S. Appl. No. 13/653,456. |
Statement of Relatedness under MPEP Jun. 2001 dated Aug. 23, 2017 with Respect to U.S. Appl. No. 13/653,456. |
Statement of Relatedness under MPEP Jun. 2001 dated Jun. 16, 2016 with Respect to U.S. Appl. No. 13/653,456. |
Statement of Relatedness under MPEP Jun. 2001 dated Sep. 25, 2017 with Respect to U.S. Appl. No. 13/653,456. |
Stevens et al. (2006) "Velocimmune: Humanization of Immunoglobulin Loc Using Velocigene Technology," First International MUGEN Conference of Animal Models for Human Immunological Disease, Sep. 10-13, 2016-Athens, Greece, Abstract 4 and Poster, 2 pages original (pp. 3-11 are p. 2 of the original, enlarged). |
Stevens et al. (2006) "Velocimmune: Humanization of Immunoglobulin Loc Using Velocigene Technology," First International MUGEN Conference of Animal Models for Human Immunological Disease, Sep. 10-13, 2016—Athens, Greece, Abstract 4 and Poster, 2 pages original (pp. 3-11 are p. 2 of the original, enlarged). |
Storb et al. (1986) "Transgenic Mice with μ and κ Genes Encoding Antiphosphorycholine Antibodies," J. Exp. Med., 164:627-664. |
Suarez et al, Molecular Immunology, 2006, 43:1827-1835. * |
Suarez et al., "Rearrangement of only one human IGHV gene is sufficient to generate a wide repertoire of antigen specific antibody responses in transgenic mice," Molecular Immunology, 43(11): 1827-1835, 2006. |
Sui et al. 2009. Nature Structural & Molecular Biology 16(3):265-273. |
Suzuki et al. 1995. Journal of Immunology 154:3902-3911. |
Taki et al. (1993) "Targeted Insertion of a Variable Region Gene into the Immunoglobuliin Heavy Chain Locus," Science, 262:1268-1271. |
Taylor et al. 1992. Nucleic Acids Research 20(23):6287-6295. |
Third Party Observations for European Patent Application No. 12783456.2 filed on Mar. 12, 2014. |
Third Party Observations with Respect to European Patent Application No. EP12783456.2, EPO Communication submitted on Feb. 25, 2015. |
Third Party Observations with Respect to European Patent Application No. EP12783456.2, EPO Communication submitted on Jun. 22, 2016. |
Tiller et al. (2013) "A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties," mAbs, 5(3):445-470 (http://www.tandfonline.com/loi/kmab20). |
Timetable for Mouse ES Cells course at Wellcome Trust Sanger Institute Oct. 26, 2009-Nov. 8, 2009 (black and white). |
Timetable for Mouse ES Cells course at Wellcome Trust Sanger Institute Oct. 26, 2009-Nov. 8, 2009 (greyscale). |
Tobin et al, Blood, 2004, 104:2879-2885. * |
Tong et al. (2010) "Production of p53 gene knockout rats by homologous recombination in embryonic stem cells," Nature Letters, 467:211-215. |
Tuaillon et al. 1993. PNAS 90:3720-3724. |
UK Decision EP1360287 and EP2264163 Feb. 1, 2016. |
UniProtKB/Swiss-Prot Accession No. P23083, HV103_Human, 7 pages, integrated into UniProtKB/Swiss-Prot Nov. 1, 1991, last modified Nov. 11, 2015, last accessed Dec. 9, 2015 <http://www.uniprot.org/P23083>. |
Vakil et al. (1991) "Antigen-Independent Selection of T15 Idotype During B-Cell Ontogeny in Mice," Developmental Immunology, 1:203-212. |
Valenzuela et al (2003) "High-throughput engineering of the mouse genome coupled with high-resolution expression analysis," Nat. Biotechnol., 21:652-659. |
Wagner et al. 1994. Nucleic Acids Research 22(8):1389-1393. |
Wagner et al., "The diversity of antigen-specific monoclonal antibodies from transgenic mice bearing human immunoglobulin gene miniloci," Eur. J. Immunol. 24: 2672-2681, 1994. |
Wagner, et al., (1996) "Antibody Expression from the Core Region of the Human IgH Locus Reconstructed in Transgenic Mice Using Bacteriophage P1 Clones," GENOMICS, 35:405-414. |
Wang & Palese. 2009. Nature Structural & Molecular Biology 16 (3):233-234. |
Wheeler, et al., (2001) "Transgenic Technology and Applications in Swine," Theriogenology, 56:1345-1369. |
Widhopf II et al, Blood, 2004, 104:2499-2504. * |
Written Opinion for PCT/US2012/060487 filed Oct. 17, 2012 dated Feb. 1, 2013, 5 pages. |
Written Opinion for PCT/US2013/029624 (12 pages), dated Aug. 2, 2013. |
Xu and Davis. 2000. Immunity 13:37-45. |
Xu et al., "Diversity in the CDR3 Region of VH Is Sufficient for Most Antibody Specificities," Immunity, 13: 37-45, 2000. |
Yamada et al. 1991. Journal of Experimental Medicine 173:395-407. |
Yantha et al. (2010) "Unexpected Acceleration of Type 1 Diabetes by Transgenic Expression of B7-H1 in NOD Mouse Peri-Islet Glia," Diabetes, 59:2588-2596. |
Zhang et al. (1998) "A new logic for DNA engineering using recombination in Escherichia coli," Nature Genetics, 20:123-138. |
Zhou et al., (2009) "Developing tTA transgenic rats for inducible and reversible gene expression," International Journal of Biological Sciences, 5:171-181. |
Zou et al. (1994) Cre-IoxP-mediated gene replacement: a mouse strain producing humanized antibodies, Current Biology, 4:1099-1103. |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200277371A1 (en) * | 2011-10-17 | 2020-09-03 | Regeneron Pharmaceuticals, Inc. | Restricted Immunoglobulin Heavy Chain Mice |
WO2022056276A1 (en) | 2020-09-11 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
WO2022132943A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11261248B2 (en) | Restricted immunoglobulin heavy chain mice | |
US11559050B2 (en) | Humanized non-human animals with restricted immunoglobulin heavy chain loci | |
NZ623102B2 (en) | Restricted immunoglobulin heavy chain mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: REGENERON PHARMACEUTICALS, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MACDONALD, LYNN;MCWHIRTER, JOHN;GURER, CAGAN;AND OTHERS;SIGNING DATES FROM 20130320 TO 20130321;REEL/FRAME:030106/0271 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |